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Endometrial cancer is the second most common cancer among female cancer survivors 
in the United States. A variety of long-term, adverse health effects have been observed among 
endometrial cancer survivors but the relationship between endometrial cancer diagnosis and 
treatment and these outcomes among survivors, years after diagnosis remains poorly 
understood. Because of the high survival rate and the increasing rate at which new cases are 
being diagnosed, examining the risk for long-term, adverse health effects among endometrial 
cancer survivors is essential. 
Cohorts of 2,648 endometrial cancer survivors diagnosed in Utah between 1997 and 
2012 and 10,503 age-matched, cancer-free women from the general population were identified. 
Electronic medical record data including all International Classification of Diseases , 9th revision 
(ICD-9) diagnosis codes from Utah’s two largest healthcare providers as well as statewide 
ambulatory surgery and inpatient records were used to capture all available cardiovascular, 
genitourinary, and gastrointestinal outcomes. Cox regression models were used to estimate risk 
for outcomes between survivors and individuals in the general population at 1-5 and >5-10 years 
after diagnosis. Cox regression models were also used to examine potential risk factors for 
various conditions among endometrial cancer survivors. 
Endometrial cancer survivors were at elevated risk for cardiovascular, genitourinary, and 
gastrointestinal disorders overall and for dozens of more specific outcomes within these 
broader categories compared to the general population. Between 1-5 years after diagnosis, 
iv 
 
endometrial cancer survivors treated with surgery in conjunction with chemotherapy and/or 
radiation were at elevated risk for heart, circulatory system, urinary system, genital organ, 
upper gastrointestinal, lower gastrointestinal, abdominal hernia, and liver disorders compared 
to those treated with surgery alone. Elevated risk for abdominal hernias and lower 
gastrointestinal disorders persisted between >5-10 years after diagnosis. 
These results present sufficient evidence that endometrial cancer survivors experience a 
greater burden of adverse cardiovascular, genitourinary, and gastrointestinal outcomes many 
years after diagnosis compared to the general population and that these outcomes may be 
related to cancer treatment. Many of these conditions contribute to increased morbidity and 
mortality and adversely affect quality of life. For these reasons, greater attention should be 
focused both on long-term surveillance and prevention of these conditions among endometrial 
cancer survivors.    
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1.1 Endometrial Cancer Incidence and Survival Statistics 
Endometrial cancer is the second most common cancer among female cancer survivors 
in the United States, the fourth most commonly diagnosed cancer among women, and the 10th 
most commonly diagnosed cancer overall.1 Endometrial cancer was the 8th most common cause 
of death from cancer among women in 2013, 7th in 2015, and the 6th in 2016, responsible for 
an estimated 10,470 deaths.2 The majority (75-80%) of women diagnosed with endometrial 
cancer are diagnosed with stage I disease. The rate of death from endometrial cancer has 
increased by >1% per year since 2003, but the current 5-year survival rate is relatively high at 
81.7% for endometrial cancer overall, 95.3% for women diagnosed with stage I disease, 68.2% in 
women diagnosed with stage II and III disease, and 16.9% for women diagnosed with IV.2 
The median age for endometrial cancer diagnosis is 62, and the majority of cases are 
diagnosed between 45 and 74 years of age.3 Women with a family history of Lynch Syndrome-
related disease (2-5% of all cases) are often diagnosed at an earlier age.4-6  Incidence rates of 
newly diagnosed endometrial cancers among women under the age of 50 have increased by 
1.3% per year since 1988 and by 1.9% per year among women over the age of 55 since 2005.2 
The increasing rate of newly diagnosed cases and high overall survival rate has led to a steadily 




an estimated 757,000 in 2016.3,7  
 
1.2 Endometrial Cancer Type and Treatment Indication 
Endometrial cancer was thought to be a single disease prior to the early 1980s, when 
clinicians observed that histologic, molecular, and behavioral characteristics suggested two 
distinct subtypes with differing etiologies.8-10 Broadly, well differentiated endometrioid 
adenocarcinomas (with or without squamous differentiation) were labeled Type I; while those 
that are higher grade papillary serous, clear cell, or several additional types of carcinoma were 
labeled Type II.11 Type I tumors comprise 80-90% of all endometrial cancer diagnoses while Type 
II tumors comprise 10-20%.11,12   
After the FIGO staging criteria was revised in 2009, these prognostic factors were used 
to further classify tumors into low, intermediate, and high risk groups for metastases to lymph 
nodes, the abdominal cavity, and to distant sites.13 Low risk endometrial cancers are 
endometrioid histology, stage IA, low grade tumors with  <50% myometrial invasion; other stage 
I tumors are intermediate risk; and high risk tumors are those that are nonendometrioid 
histology, stage IB or higher, grade 3, and >50% myometrial invasion.13,14  
Treatment for endometrial cancer in almost all cases involves total hysterectomy 
(usually with bilateral salpingo-oophorectomy).15 The use of adjuvant radiation therapy, either 
external beam and/or brachytherapy, or chemotherapy varies by stage, grade, and histology at 
diagnosis; and lymphadenectomy is performed depending on grade, depth of myometrial 
invasion, and tumor size.16 Using data from SEER and the National Cancer Database in 2013, it 
was estimated that 69% of those diagnosed with stage I or II endometrial cancer were treated 
with surgery alone, while 17% were treated with surgery and radiation therapy, 5% with surgery 




chemotherapy and radiation therapy.17 For those diagnosed with stage III and IV endometrial 
cancer, 16% were treated with surgery alone, 28% with surgery and radiation therapy, 33% with 
surgery and chemotherapy, 5% with surgery, radiation therapy, and chemotherapy, and 12% 
with chemotherapy and radiation therapy. 
 
1.3 Long-Term, Adverse Health Effects Among Endometrial Cancer Survivors 
The majority of studies that have examined long-term adverse health outcomes among 
endometrial cancer survivors have focused primarily on health-related quality of life, mental 
health, obesity, and adverse sexual side effects. The studies that have measured specific 
cardiovascular, genitourinary, and gastrointestinal outcomes often include small numbers of 
individuals, lack control groups, lack validated outcome measures, measure symptoms that are 
secondary to an underlying cause, or suffer from loss to follow-up, making risk for these 
conditions difficult to quantify. The use of self-reported data from questionnaires to measure 
gastrointestinal and genitourinary outcomes may include questions about conditions that 
patients are reluctant to report.  
 
1.3.1 Cardiovascular Outcomes 
A study using Surveillance, Epidemiology, and End Results Program (SEER) data between 
1973 and 1988 reported that cardiovascular disease was the leading cause of death among 
33,233 endometrial cancer survivors.18 The proportion of women diagnosed with Type I 
endometrial cancer in this cohort who died of cardiovascular disease (42.1%) was higher than 
the proportion of all women who died of cardiovascular disease during that same time period 




and 2002 that reported that the proportion of endometrial cancer survivors who died of 
cardiovascular disease was greater than those who died of any other cause.20  
The relationship between endometrial cancer and cardiovascular disease is complicated 
due to shared risk factors.21 The proportion of the American population that is obese has more 
than doubled since 1960, from 15.8% to 36.6%; and the proportion that is extremely obese is 
more than 6 times greater than in 1960, from 1.4% to 8.6%.22 Heart disease and hypertension 
are likely common among endometrial cancer survivors23 due to obesity, but there have been 
few studies sufficiently powered to examine the risk for more specific cardiovascular outcomes 
among endometrial cancer populations compared to the general population. The relationship 
between treatment with radiation therapy and cardiovascular disease is poorly understood, but 
there is evidence that treatment with chemotherapy can increase the risk of heart failure and 
cardiomyopathy.24 
 
1.3.2 Genitourinary Outcomes 
Adverse genitourinary conditions due to treatment for endometrial cancer are among 
the most commonly reported complications reported among endometrial cancer survivors. 
Long-term surveillance of surgically treated patients has suggested that regional complications 
due to surgery are usually resolved within 1 year, while treatment with radiation therapy can 
cause damage to tissue architecture of the genital and urinary systems that can persist for years 
after treatment cessation.25-27  
In a comparison of urinary incontinence among survivors of several different cancer 
types, 40.2% of endometrial cancer survivors experienced urinary incontinence, which was 
higher than any of the other cancers examined (breast, prostate, bladder, colorectal, and lung), 




urinary urgency, daytime leakage at least once a day, bladder pain, and nocturia. They are 2-5 
times more likely to experience symptoms of urinary incontinence after 1 year of treatment 
cessation.29 Endometrial cancer patients treated with external beam radiation therapy were at 
higher risk for urinary incontinence compared to those treated with brachytherapy at 7 and 10 
years after diagnosis.30 Additionally, there is evidence that the combination of external beam 
radiation therapy and brachytherapy increases the risk of long-term urinary complications 
compared to external beam radiation therapy or brachytherapy alone.31  
There is evidence that individuals treated with radiation therapy for gynecologic 
malignancies may experience renal toxicity,32 but very few studies have examined the 
relationship between radiation therapy therapy and specific renal outcomes among endometrial 
cancer survivors; and they have produced mixed results. 
 
1.3.3 Gastrointestinal Outcomes 
In a retrospective study that examined treatment related complications among high-risk 
endometrial cancer patients (n=109), 66% of individuals who experienced any complications had 
either adverse gastrointestinal or genitourinary outcomes.33 Among those who experienced GI 
complications, 14% were short term (<6 months) and 29% were long-term (>6 months). 
Increased risk for diarrhea, pain, nausea, bloating, bowel obstructions, rectal bleeding, fecal 
incontinence, and urgency due to radiation therapy induced bowel damage has been observed 
among endometrial cancer patients years after diagnosis34-36. Adverse gastrointestinal outcomes 
among cancer survivors are often overlooked due to the priority of surveillance for disease 
recurrence, but gastrointestinal symptoms remain among the most common complications of 
treatment and have the greatest impact on quality of life.37  
 
6 
Treatment with external beam radiation therapy has been associated with adverse 
gastrointestinal outcomes among endometrial cancer survivors.38,39 However, gastrointestinal 
outcomes have typically been measured in broad categories in populations <1,000 endometrial 
cancer survivors with broad variation in the length of time since diagnosis. Individuals treated 
with external beam radiation therapy have been observed to have more gastrointestinal 
complications within 5 years after diagnosis than those treated with brachytherapy, including 
diarrhea, leakage, and the need to stay within close proximity to a toilet, all of which limit daily 
activities.40 
1.4 The Current Study 
The three specific aims of this study are to compare the risk of a wide range of long-
term (1) cardiovascular, (2) genitourinary, and (3) gastrointestinal outcomes between 
endometrial cancer survivors and individuals from the general population, as well as examine 
risk factors for a number of specific long-term outcomes among endometrial cancer survivors 1-
5 years and >5-10 years after diagnosis. These risk factors include treatment type, stage, grade, 
and age at diagnosis, baseline body mass index, and baseline Charlson Comorbidity Index.  
Cohorts of 2,648 women diagnosed with endometrial cancer and 10,503 matched 
individuals from the general population were identified using the Utah Population Database. 
Electronic medical record data containing all ICD-9 diagnosis codes from Utah’s two largest 
healthcare providers as well as statewide ambulatory surgery and inpatient records were used 
to capture outcomes. The current study is one of the largest population-based cohort studies 
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Endometrial cancer is the second most common cancer among female cancer survivors 
in the US, with an estimated 757,000 endometrial cancer survivors in 2016. Cardiovascular 
disease is the leading cause of death among endometrial cancer survivors. Risk for 
cardiovascular disease may be increased among endometrial cancer survivors due to shared risk 
factors such as obesity or due to the effects of cancer treatment. Because of the high overall 
survival rate and the large number of endometrial cancer survivors, studies that examine late 
effects among endometrial cancer survivors are critical.  
Cohorts of 2,648 endometrial cancer survivors diagnosed in the state of Utah between 
1997 and 2012, and 10,503 age-matched women from the general population were identified 
using the Utah Population Database. All ICD-9 diagnosis codes were collected from Utah’s two 
largest healthcare systems in addition to statewide ambulatory surgery and inpatient visits. Cox 
regression models were used to estimate hazard ratios (HR) at 1-5 years and >5-10 years after 
cancer diagnosis. Models were adjusted for matching factors, race/ethnicity, baseline body mass 
index (BMI), and baseline Charlson Comorbidity Index.   
Between 1-5 years after diagnosis, the some of the highest cardiovascular risks among 




thromboembolism (HR: 2.24, 99% CI: 1.63-3.08), lymphatic diseases (HR: 1.86, 99% CI: 1.62-
2.14), pulmonary heart disease (HR: 1.82, 99% CI: 1.36-2.43), hypotension (HR: 1.85, 99% CI: 
1.29-2.65), and atrial fibrillation (HR: 1.44, 99% CI: 1.02-2.02).  At >5-10 years, elevated risk 
persisted for many of these diseases and other cardiovascular disease outcomes among the 
endometrial cancer survivors. In comparison to endometrial cancer patients who had surgery, 
patients who additionally had radiation therapy and/or chemotherapy were at increased risks 
for heart and circulatory system disorders at 1-5 years, but not at >5-10 years after cancer 
diagnosis.  Obesity at cancer diagnosis contributed to increased risks of hypertension and 
diseases of the heart.  
Endometrial cancer survivors in this population are at higher risk for various adverse 
long-term cardiovascular outcomes compared to women from the general population. This 
study suggests that increased monitoring for diseases of the cardiovascular system may be 
necessary for women diagnosed with endometrial cancer during the first several years after 
diagnosis and continued care throughout the life course. 
 
2.2 Introduction 
Endometrial cancer is the 4th most commonly diagnosed cancer among women in the 
United States and the second most common cancer among female cancer survivors.1 Incidence 
rates among women under the age of 50 have been increasing by 1.3% per year since 1988 and 
by 1.9% among women over the age of 50 since 2005.2 It was the 6th most common cause of 
death from cancer among women in the United States in 2016, with an estimated 10,470 
deaths, having been 7th most common in 2015 and 8th most common in 2013.2  Since 2003, 
rates of death due to endometrial cancer have increased by 1.1% per year. As of 2016, there 




Endometrial cancer survivors are a relatively young population with high survival rates.  
The average age at diagnosis is 62, with the majority of endometrial cancers being diagnosed in 
women over the age of 55.3,4 Women with a family history of hereditary nonpolyposis colon 
cancer (Lynch syndrome) are often diagnosed at an earlier age5-7. The current 5-year survival 
rate in the United States is 81.7% for endometrial cancer overall, 95.3% for women diagnosed 
with stage I disease, 68.2% in women diagnosed with stage II and III disease, and 16.9% for 
women diagnosed with stage IV.2 However, little is known about the long-term health effects 
associated with endometrial cancer and whether treatment type moderates these effects.   
Previous studies on the long-term health effects among endometrial cancer survivors 
have focused largely on quality of life, mental health, obesity, and adverse sexual side effects; 
though there have been several studies that have examined long-term cardiovascular outcomes 
among endometrial cancer survivors.8-10 A 2015 study among long-term survivors of breast, 
prostate, colorectal, ovarian, and endometrial cancers found that endometrial cancer survivors 
(n=194) were diagnosed with an average of 2.4 comorbid conditions after their cancer diagnosis, 
which was second only to breast cancer survivors (with 2.9 comorbid conditions).4 In addition, 
21.2% of endometrial cancer survivors in their cohort experienced at least 1 adverse 
cardiovascular outcome after cancer diagnosis, a proportion that was higher than that of 
survivors of any of the other cancer sites.  
Based on SEER data, cardiovascular disease was reported to be the leading cause of 
death greater than 5 years after cancer diagnosis among 33,233 endometrial cancer survivors 
diagnosed between 1973 and 1988.8 The proportion of women diagnosed with localized, low 
grade endometrial cancer who died of cardiovascular disease in this population (42.1%) was 
higher than the proportion of all women who died of cardiovascular disease during that same 




endometrial cancer, the proportion of individuals who died of cardiovascular disease was 
greater than that of endometrial cancer, other malignancies, and other causes of death. 
Similarly, a study published in 2017 that examined mortality among endometrial cancer 
survivors diagnosed between 1988 and 2002 reported that between 5 and 10 years after 
diagnosis, endometrial cancer survivors were more likely to die of cardiovascular disease than of 
endometrial cancer, other malignancies, and other causes.10 
 Obesity is a risk factor for both endometrial cancer and cardiovascular disease.8 The 
proportion of the American population that is obese has more than doubled since 1960, from 
15.8% to 36.6%; and the proportion that is extremely obese is more than 6 times greater than in 
1960, from 1.4% to 8.6%.9 This increase in the prevalence of obesity in conjunction with changes 
in other endometrial cancer risk factors such as diabetes,13 fertility,14 intrauterine device use,15,16 
hormone therapy use,17 and elective hysterectomy18 may contribute to the increased incidence 
of endometrial cancer observed over the past several decades. 
While there have been a number of studies that have examined long-term cardiovascular 
outcomes among endometrial cancer survivors, many of these have included small sample sizes, 
lacked control groups, measured broad outcome categories, or lacked validated outcome 
measures.  
Studies that examine risk for long-term cardiovascular outcomes among endometrial 
cancer survivors using reliable data from electronic medical records are becoming increasingly 
more critical because of the high overall survival rate among individuals diagnosed with 
endometrial cancer, the large number of endometrial cancer survivors, the projected increase in 
the number of endometrial cancer diagnoses over the next several decades,19 the introduction 
of more complex therapies, and the high mortality due to cardiovascular disease among 





2.3.1 Data Collection 
An initial cohort of 3,624 endometrial cancer survivors was identified using the Utah 
Population Database.  Diagnosis data were available from the statewide SEER Utah Cancer 
Registry for women aged 18 and over, diagnosed with invasive first primary endometrial cancer 
between 1997 and 2012 in the state of Utah (SEER International Classification of Diseases for 
Oncology (ICD-O-3) codes: C54.0-C55.9). Endometrial cancer histological subtypes 
adenocarcinoma, endometrioid, mucinous adenocarcinoma, and adenocarcinoma with 
squamous differentiation were classified as Type I (ICD-O-3 morphology codes: 8140, 8260, 
8380, 8382, 8480, 8482, 8560, and 8570) and clear-cell carcinomas and papillary serous 
carcinomas as Type II (ICD-O-3 morphology codes: 8310, 8441, and 8460)20. Survivors were 
matched on birth year and birth state with up to 5 women from the general population.   
Outcome data used for this study included statewide ambulatory and inpatient data 
from the Utah Department of Health and Electronic Data Warehouse data from Intermountain 
Health Care and the University of Utah Health Sciences Center. The Utah Population Database  
data included records from the Utah Cancer Registry, Utah Driver’s License, vital records, and 
the Utah Department of Health. Statewide ambulatory and inpatient records as well as those 
from the University of Utah and Intermountain Healthcare systems were linked via the Utah 
Population Database.  
Electronic medical record data was available prior to 1992, but all three major sources 
did not have comprehensive electronic medical record data for individuals in these cohorts until 
1996. Individuals diagnosed with endometrial cancer between 1997 and 2012 were included in 
this analysis to allow adequate time prior to cancer diagnosis to capture prior diagnoses of the 




because their cancer was not staged, 470 because grade was missing, 285 because follow up 
time did not exceed 1 year, 65 because their Utah residence did not exceed 1 year. The stage 
and grade were necessary for our sample because we were interested in their potential role in 
risk for the outcomes measured in this study. There were a total of 2,648 endometrial cancer 
survivors included in the final sample.   
 
2.3.2 Categorization of Outcomes 
Outcome data from the statewide, University of Utah Health Sciences Center, and 
Intermountain Healthcare systems included all available ICD-9 diagnosis codes, as well as 
diagnosis date which allowed for time to outcome to be calculated). The Clinical Classification 
Software developed by the Health Cost and Utilization Project was used to categorize ICD-9 
codes into 4 levels of specificity (Levels 1-4).21 Diseases of the cardiovascular system (level 1) 
according to the Clinical Classification Software were used in this analysis.  Level 2 outcomes 
included hypertension, diseases of the heart, cerebrovascular diseases, diseases of the arteries, 
arterioles, and capillaries, and diseases of the veins and lymphatics. More specific outcomes 
within these categories were analyzed as level 3 and 4 outcomes. Examples of this hierarchy 
include diseases of the heart (level 2), heart valve disorders (level 3), chronic rheumatic disease 
of the heart valves (level 4), and cerebrovascular disease (level 2), acute cerebrovascular disease 
(level 3), and intracranial hemorrhage (level 4).  
Long-term cardiovascular outcomes were measured at 1-5 years and >5-10 years after 
endometrial cancer diagnosis. Follow-up time for incident cases of each outcome was calculated 
separately from the endometrial cancer survivor’s initial cancer diagnosis to the date of 
diagnosis for each outcome, last date of follow-up, or date of death. Individuals who did not 




death) if that date fell within the analysis time period (1-5 years or >5-10 years) or at the end of 
each analysis time period if their date of last-follow-up exceeded the end of the analysis time 
period. Level 3 or 4 outcomes diagnosed prior to the start of each analysis time period were 
considered prevalent cases of those outcomes and individuals were excluded from the relevant 
models.  Level 1 and 2 outcomes were broader and contained multiple disparate conditions, 
thus we did not exclude prevalent diagnoses.    
 
2.3.3 Statistical Analysis 
Chi-square tests were used to compare baseline characteristics between the cancer and 
general population cohorts. Univariate and multivariate Cox proportional hazard models were 
used to calculate hazard ratios for long-term cardiovascular outcomes at 1-5 years and >5-10 
years after endometrial cancer diagnosis. We used 99% confidence intervals to account for the 
penalty imposed by multiple testing due to the large number of outcomes examined in this 
analysis. Multivariate models were adjusted for matching factors, baseline body mass index 
(BMI), baseline Charlson Comorbidity Index, and race. Cox proportional hazard models were also 
used to investigate risk factors such as treatment type, stage, grade, age at diagnosis, year of 
diagnosis, race, BMI, and rural/urban residence for hypertension, heart disease, diseases of the 
arteries, arterioles, and capillaries, and diseases of the veins and lymphatics among endometrial 
cancer survivors. The proportional hazards assumption was checked for each model using a test 
for nonzero slope of the Schoenfeld residuals vs time. Models that were in violation of the 
proportional hazards assumption were then tested with flexible parametric survival models with 
restricted cubic splines. Hazard ratios from the Cox proportional hazard models were reported 





Baseline BMI values at least 1 year prior to cancer survivors’ endometrial cancer 
diagnosis were calculated from the driver’s license records.  For the cancer-free women, the 
most recent BMI value recorded at least 1 year prior to the endometrial cancer diagnosis date of 
the matched cancer patient was included. Approximately 35% of the survivors cohort and 39% 
of the general population cohort were missing baseline BMI. For individuals missing BMI, BMI 
values were imputed using a linear regression model with 10 imputations that included cancer 
diagnosis, baseline Charlson Comorbidity Index,22 and age at endometrial cancer diagnosis as 
covariates. Models were run with and without the imputed values to assure that the inferences 
did not change due to the imputation of BMI.  
 
2.4 Results 
The endometrial cancer survivors cohort had a higher proportion of obese individuals 
(44.2% vs 19.2%) than the general population cohort (p<0.001; Table 2.1). Approximately 
81.53% of the endometrial cancer survivors were diagnosed with low grade tumors, and 80.3% 
with stage I disease (Table 2.2).  
Elevated risks for hypertension were observed among endometrial cancer survivors 
compared to the general population cohort (Table 2.3) between 1-5 years (HR: 1.51, 99% CI: 
1.36-1.67) and between >5-10 years (HR: 1.44, 99% CI: 1.28-1.62) after diagnosis .  
Approximately 5.5% of endometrial cancer patients were diagnosed with cerebrovascular 
disease, but an increased risk was not observed compared to the general population cohort. 
Increased risks for multiple circulatory system diseases were observed 1-5 years after 
cancer diagnosis (Table 2.4).   Endometrial cancer survivors were 44% more likely to be 
diagnosed with diseases of arteries, arterioles, and capillaries during both time periods. Elevated 




vascular atherosclerosis, hypotension, phlebitis, thrombophlebitis, thromboembolism, other 
circulatory diseases, and other diseases of the veins and lymphatics.  
Approximately 25.7% of cancer survivors were diagnosed with diseases of the heart 
compared to 21.7% of individuals in the general population cohort >5-10 years after cancer 
diagnosis (Table 2.5). Endometrial cancer survivors were 44% more likely to be diagnosed with a 
disease of the heart between 1-5 years and 50% more likely between >5-10 years after 
diagnosis. Elevated risk among endometrial cancer survivors was observed for cardiac 
dysrhythmias, nonhypertensive congestive heart failure, and congestive heart failure overall at 
both 1-5 and >5-10 years after diagnosis. Endometrial cancer survivors had a higher risk of 
developing heart valve disorders, premature beats, and other/ill-defined heart disease at >5-10 
years after diagnosis, but not at 1-5 years. 
Among endometrial cancer survivors, 68.5% were treated with surgery alone, 21.9% 
with surgery and radiation therapy, 3.2% with surgery and chemotherapy, and 4.7% with 
surgery, radiation therapy, and chemotherapy. Among individuals treated with radiation therapy 
and/or chemotherapy in addition to surgery, elevated risks were observed for diseases of 
arteries, diseases of veins/lymphatics and heart disease at 1-5 years compared to those treated 
with surgery alone. These increased risks did not persist in the >5-10 year time period.  
Higher BMI was an important risk factor for hypertension and heart disease among 
endometrial cancer survivors, with both overweight and obese individuals having higher risk at 
both 1-5 and >5-10 years after cancer diagnosis (Table 2.6). Obese individuals also had elevated 
risk of diseases of arteries at 1-5 years. Risk for hypertension, heart disease, and diseases of 
arteries, arterioles, and capillaries increased with each 10-year interval of age at diagnosis 
compared to those diagnosed prior to age 50 at time period. This association was observed for 




Charlson Comorbidity Index at baseline also appeared to be important risk factors for these 
diseases among endometrial cancer survivors. 
Figure 2.1 illustrates the comparison of cumulative incidences of newly diagnosed 
pulmonary heart disease, congestive heart failure, phlebitis and thrombophlebitis, hypertension 
with complications/secondary complications over the span of 1-10 years after endometrial 
cancer diagnosis between endometrial cancer survivors and the general population cohort.  
Stratified analysis comparing risk between those diagnosed with Type I vs Type II endometrial 
cancer in this cohort showed a clear trend towards larger effect sizes among those diagnosed 
with Type II endometrial cancer where risk was significantly higher among endometrial cancer 
survivors overall. These individuals are both more likely to have received radiation therapy and 
to be treated at a higher dose. 
 
2.5 Discussion 
This study is the first to examine risk for all available cardiovascular outcomes in the 
electronic medical records of several thousand endometrial cancer survivors and matched 
controls from the general population in a large cohort study. Prior studies that have examined 
long-term, adverse outcomes among endometrial cancer survivors have tended to focus either 
on a narrower range of outcomes or have sought to examine the effects related to specific 
treatments. The results of this study indicate strong evidence that endometrial cancer survivors 
are at higher risk for a wide range of adverse cardiovascular outcomes years after cancer 
diagnosis. Of the 5 major cardiovascular disease categories examined, endometrial cancer 
survivors were at higher risk for hypertension, diseases of the arteries, arterioles and capillaries, 
diseases of the veins and lymphatics, and diseases of the heart at both 1-5 and >5-10 years after 




Cerebrovascular disease was the only major category for which no clearly increased risk was 
observed among survivors. Among endometrial cancer survivors, our results suggest that risk for 
heart disease is elevated among individuals treated with chemotherapy compared to those who 
were treated with surgery alone. Similarly, elevated risk was observed for arterial and 
venous/lymphatic disease among those treated with radiation therapy and/or chemotherapy in 
conjunction with surgery compared to those treated with surgery alone.  
At 1-5 years and >5-10 year after cancer diagnosis, survivors were more likely to be 
diagnosed with hypertension than individuals from the general population. Additionally, 
survivors were more than 60% more likely to be diagnosed with secondary hypertension or 
hypertensive heart or renal disease. Among endometrial cancer survivors, the strongest 
predictors for increased risk of hypertension were being overweight or obese, increased age, 
and higher Charlson Comorbidity Index. Risk did not vary by treatment type, stage, or grade. Our 
findings provide further evidence for the strong association between shared risk factors for both 
endometrial cancer and hypertension, specifically increased age, higher BMI, and having 
multiple comorbidities. Prior studies have reported similar proportions of endometrial cancer 
survivors who have received a diagnosis of hypertension (43-47%),23,24 but this study is the first 
to quantify risk for hypertension among endometrial cancer survivors compared to the general 
population. 
The highest risk among endometrial cancer survivors in this study was observed for 
phlebitis, thrombophlebitis, and thromboembolism. Hypotension can occur in conjunction with 
pulmonary embolism, deep vein thrombosis, venous thromboembolism, and other circulatory 
system disorders25 and the elevated risk of hypotension among endometrial cancer survivors in 
this study may be related to these conditions. For these circulatory system disorders, it is 




implicated.26 The increased risk for circulatory system disorders among survivors treated with 
radiation therapy and/or chemotherapy support previous findings that risk for these conditions 
is elevated among survivors of lymphoma, breast cancer, and head and neck cancer who were 
treated with radiation therapy27 and among individuals treated with chemotherapy for a variety 
of cancers.28 
For diseases of the heart, elevated risk for chest pain and pulmonary heart disease was 
observed at 1-5 years but not at >5-10 years. Individuals diagnosed with endometrial cancer 
were approximately 50% more likely to be diagnosed with cardiac dysrhythmias and congestive 
heart failure than individuals in the general population at both 1-5 years and >5-10 years after 
cancer diagnosis. Both have well established associations with obesity and a number of 
additional cardiovascular diseases, including hypertension, myocarditis, myocardial infarction, 
and cardiomyopathy.29,30 While cardiomyopathy and myocardial infarction risk was similar to 
that of the general population, other peri/endo/myocarditis diseases were more common in 
endometrial cancer survivors. Cardiac dysrhythmias and congestive heart failure as a result of 
cancer treatment have more often been associated with pharmacologic interventions than with 
radiation therapy,31,32 and the increased risk for heart disease overall among survivors treated 
with chemotherapy, in conjunction with surgery and/or radiation therapy compared to those 
treated with surgery alone support this evidence. Our results suggest that cancer treatment 
increasing the risk of cardiovascular disease was largely confined to the 1-5 years after cancer 
diagnosis and that treatment with chemotherapy was an important factor.  
This study has a number of significant strengths. The large sample size (>2,500 
endometrial cancer survivors and >10,000 cancer free women) provides a study population large 
enough to be sufficiently powered to examine a large number of potential outcomes without 




a study intended to encapsulate the experience of endometrial cancer survivors over a long 
period of time. The data used in this study incorporates medical records from the state’s two 
largest healthcare providers (Intermountain Healthcare and University of Utah Health Sciences 
Center) as well as statewide ambulatory surgery and inpatient data, which provides 
comprehensive medical record data for a large number of individuals. In addition to the large 
sample size, these data contain a large amount of follow-up time for individuals in both cohorts. 
The mean follow-up time among survivors is 8.5 years. Approximately 27% have total follow-up 
time between 1 and 5 years, 39% between 5 and 10 years, and 34% in excess of 10 years. In 
contrast to cancer survivor studies that rely on self-reports of disease which are susceptible to 
survival bias, our study is less susceptible to survival bias because we used long-term health 
records as the source of disease diagnoses. 
This study also has a number of limitations. While the data used for this study are 
comprised of comprehensive electronic medical record data from the two largest healthcare 
systems in the state, as well as statewide ambulatory surgery and inpatient data, there remains 
the possibility that study participants will have been diagnosed with outcomes of interest to 
these analyses in hospitals and clinics not covered by the data sources. However, approximately 
99.6% of cancer patients and 98.5% of the general population cohort did have records in these 
data sources. Additionally, because 42.7% of individuals in the survivor cohort were diagnosed 
after 2006, the potential to examine risk for these outcomes after 10 years is limited due to lack 
of follow-up time for this proportion of the study population. However, with the Utah 
Population Database as a data source, we are able to update our analysis on a regular basis.  
Another limitation of this study concerns the lack of baseline BMI data. It was required that 
baseline BMI be recorded at least 1 year prior to the survivor’s cancer diagnosis. This decision 




period when BMI could be affected by development of endometrial cancer in the cancer 
survivors cohort. This issue was addressed by imputing baseline BMI for those individuals with 
missing values using endometrial cancer status, age at diagnosis, and baseline Charlson 
Comorbidity Index.  We assured that the inferences for our results did not change whether we 
used the original BMI variable or the BMI variable with subjects with missing BMI having 
imputed values.  
While data were available to investigate treatment related risk factors among 
endometrial cancer survivors, these data were limited to broad treatment categories and did 
not include potentially informative factors such as radiation therapy type and dosage, specific 
chemotherapy agents, and duration of treatment. However, the treatment data that were 
available did provide evidence that risk for several cardiovascular outcomes vary by treatment 
type. Additional research is also needed to determine the contribution of diet and physical 
activity to these outcomes to better understand the causal relationship between treatment type 
and the outcomes examined in this study. 
In conclusion, endometrial cancer survivors in this cohort were at higher risk for a 
number of long-term cardiovascular outcomes. These results present a wide range of outcomes 
encompassing hypertension, diseases of the heart, cerebrovascular diseases, diseases of the 
arteries, arterioles, and capillaries, and diseases of the veins and lymphatics. Many of the 
conditions examined in this study have shared risk factors with endometrial cancer, making it 
difficult to disentangle the effects of the disease or its treatment. Despite this, it is clear from 
these results that the survivors of endometrial cancers in this cohort experienced a high burden 
of cardiovascular events. These results highlight the importance of placing greater emphasis on 
survivorship and that increased monitoring for cardiovascular disease over long periods of time 





1. Centers for Disease Control and Prevention. Cancer among women. cdc.gov. 
http://www.cdc.gov/cancer/dcpc/data/women.htm. Accessed February 24,2017. 
2. American Cancer Society. Cancer Facts & Figures 2016. cancer.org. 
http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-
047079.pdf. Accessed February 24,2017. 
3. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER 
stat fact sheets: Endometrial Cancer. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 
February 24,2017. 
4. Leach CR, Weaver KE, Aziz NM, et al. The complex health profile of long-term cancer 
survivors: prevalence and predictors of comorbid conditions. J Cancer Surviv. 2015 Jun;9(2):239-
51. 
5. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death 
among endometrial cancer patients. Gynecol Oncol. 2012;126:176-9. 
6. Lynch HT, Lanspa S, Smyrk T, et al. Hereditary nonpolyposis colorectal cancer (Lynch 
syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet 
Cytogenet. 1991 Jun;53(2):143-60. 
7. Daniels MS, Lu KH. Genetic predisposition in gynecologic cancers. Semin Oncol. 2016 
Oct;43(5):543-547. 
8. Singh S, Resnick KE. Lynch Syndrome and Endometrial Cancer. South Med J. 2017 
Apr;110(4):265-269. 
9. Centers for Disease Control and Prevention. 75 Years of Mortality in the United States, 
1935–2010. cdc.gov. http://www.cdc.gov/nchs/data/databriefs/db88.htm#x2013;2010</a>. 
Accessed 3/24/2017. 
10. Felix AS, Bower JK, Pfeiffer RM, et al. High cardiovascular disease mortality after 
endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results 
(SEER) Database. Int J Cancer. 2017 Feb 1;140(3):555-564. 
11. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Anthropometric factors and endometrial 
cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann 
Oncol. 2015 Aug;26(8):1635-48. 
12. Fryar CD, Carroll MD, Ogden CL. Prevalence of overweight, obesity, and extreme obesity 
among adults: United States, 1960–1962 through 2011–2012. National Center for Health 
Statistics, 2011. cdc.gov. 
http://www.cdc.gov/nchs/data/hestat/obesity_adult_11_12/obesity_adult_11_12.htm. 
Accessed February 24,2017. 
13. Vrachnis N, Iavazzo C, Iliodromiti Z, et al. Diabetes mellitus and gynecologic cancer: 




Obstet. 2016 Feb;293(2):239-46. 
14. La Vecchia C1, Negri E, Franceschi S, et al. Long-term impact of reproductive factors on 
cancer risk. Int J Cancer. 1993 Jan 21;53(2):215-9. 
15. Benshushan A, Paltiel O, Rojansky N, et al. IUD use and the risk of endometrial cancer. 
Eur J Obstet Gynecol Reprod Biol. 2002 Nov 15;105(2):166-9.  
16. Beining RM, Dennis LK, Smith EM, et al. Meta-analysis of intrauterine device use and risk 
of endometrial cancer. Ann Epidemiol. 2008 Jun;18(6):492-9. 
17. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for 
perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 
17;1:CD004143. 
18. Wright JD, Herzog TJ, Tsui J, et al. Nationwide trends in the performance of inpatient 
hysterectomy in the United States. Obstet Gynecol. 2013 Aug;122(2 Pt 1):233-41. 
19. Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: 
should we be concerned? Future Oncol. 2014 Dec;10(16):2561-8. 
20. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II 
endometrial cancer. Cancer Causes Control. 2010 Nov;21(11):1851-6. 
21. Healthcare Cost and Utilization Project. Clinical Classification Software. 
https://www.hcup-us.ahrq.gov/tools_software.jsp. Accessed November 21, 2016. 
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-
83. 
23. von Gruenigen VE, Waggoner SE, Frasure HE, et al. Lifestyle challenges in endometrial 
cancer survivorship. Obstet Gynecol. 2011 Jan;117(1):93-100. 
24. Nicholas Z, Hu N, Ying J, et al. Impact of comorbid conditions on survival in endometrial 
cancer. Am J Clin Oncol. 2014 Apr;37(2):131-4. 
25. Yin XH, Jia HY, Xue XR, et al. Clinical analysis of endometrial cancer patients with obesity, 
diabetes, and hypertension. Int J Clin Exp Med. 2014 Mar 15;7(3):736-43. 
26. Fajardo LF, Berthrong M. Vascular lesions following radiation. Pathol Annu. 1988;23 Pt 
1:297-330. 
27. Weintraub NL, Jones WK, Manka D. Understanding Radiation-Induced Vascular Disease. 
J Am Coll Cardiol. 2010 Mar 23; 55(12): 10. 
28. Cameron AC, Touyz RM, Lang NN. Vascular Complications of Cancer Chemotherapy. Can 
J Cardiol. 2016 Jul;32(7):852-62. 
29. LaMori JC, Mody SH, Gross HJ, et al. Burden of comorbidities among patients with atrial 




30. Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring 
and management. J Clin Med Res. 2009 Apr;1(1):8-12. 
31. Ewer MS, Benjamin RS, Yeh ET. Cardiac dysrhythmia in the cancer patient. Holland-Frei 
Cancer Medicine. 6th edition. Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Hamilton 
(ON): BC Decker; 2003. 
32. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: 













population   
  n=2,648 n=10,503   
  n  % n % p 
Birth Year           
<1920 116 4.38 473 4.50   
1920-1929 310 11.71 1,192 11.35   
1930-1939 541 20.43 2,015 19.18   
1940-1949 787 29.72 3,085 29.37   
1950-1959 591 22.32 2,444 23.27   
>1960 303 11.44 1,294 12.32 0.54 
Race           
White 2,525 95.35 9,617 91.56   
Black 10 0.38 29 0.28   
American 
Indian/Alaskan Native 111 1.06 32 1.21   
Asian 277 2.64 19 0.72   
Pacific Islander 60 0.57 48 1.81   
Unknown 14 0.53 409 3.89 <0.001 
Vital Status           
        Alive 1,924 72.66 8,906 84.79   
        Dead 724 27.34 1,597 15.21 <0.001 
Baseline BMI           
        <18 kg/m2 18 0.68 307 2.92   
        18-24.9 kg/m2 645 24.36 4,994 47.55   
        25-29.0 kg/m2 814 30.74 3,190 30.74   
        >30 kg/m2 1,171 44.22 2,012 19.16 <0.001 
Age Attained at the End of 
Follow-up           
        <50 161 6.08 697 6.64   
        50-59 389 14.69 1,697 16.16   
        60-69 826 31.19 3,142 29.92   
        70-79 692 26.13 2,637 25.11   
        80-89 442 16.69 1,787 17.01   
        90+ 138 5.21 543 5.17 0.303 
Follow up Period           
        1-5 years 726 27.42 2,742 26.11   
        >5-10 years 1,028 38.82 4,062 38.67   
        >10-15 years 595 22.47 2,576 24.53   






 Table 2.2: Clinical characteristics among endometrial cancer survivors 
 
Endometrial Cancer (n=2,648) 
Diagnosis Year n % 
        1997-2000 563 21.26 
        2001-2003 471 17.79 
        2004-2006 483 18.24 
        2007-2009 572 21.60 
        2010-2012 559 21.11 
Age at Diagnosis     
        <40 140 5.29 
        40-49 307 11.59 
        50-59 786 29.68 
        60-69 758 28.63 
        70-79 451 17.03 
        80+ 206 7.78 
Grade     
        Grade I (Well differentiated)  1,314 49.62 
        Grade II (Moderately differentiated)  845 31.91 
        Grade III (Poorly differentiated) 421 15.90 
        Grade IV (Undifferentiated) 68 2.57 
Stage     
        Local 10,565 80.34 
        Regional 2,154 16.38 
        Advanced 432 3.28 
Histology     
        Endometrioid adenocarcinoma 1,853 69.98 
        Adenocarcinoma with squamous differentiation 56 2.11 
        Serous adenocarcinoma 87 3.29 
        Clear cell adenocarcinoma 17 0.64 
        Mixed cell adenocarcinoma 47 1.77 
        Mucinous adenocarcinoma 45 1.70 
        Carcinosarcoma 26 0.98 
        Stromal sarcoma 44 1.66 
        Leiomyosarcoma 41 1.55 
        Other 432 16.31 
Endometrial Cancer Type     
        Type I 2,300 86.86 
        Type II 87 3.29 
        Unknown 261 9.86 
Treatment Type   
        Surgery only 1,813 68.47 
        Surgery and radiation 579 21.87 
        Surgery and chemotherapy 84 3.17 
        Surgery, radiation, and chemotherapy 124 4.68 






 Table 2.3:  Hypertension and cerebrovascular disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors 





















Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race. 
*Models in violation of the proportional hazards assumption that were evaluated using flexible parametric survival models with restricted cubic 
splines. The following outcomes were evaluated but no elevated risk was observed: other hypertensive complications, intracranial hemorrhage, 
acute but ill-defined cerebrovascular event, other and ill-defined cerebrovascular disease, late effects of cerebrovascular disease.
  1-5 Years 
 Survivors General Population  
  n % n % HR 99% CI 
Hypertension 1,237 46.7 3,431 32.7 1.51* (1.36-1.67) 
Essential hypertension 202 17.3 1,165 16.1 0.99 (0.78-1.26) 
Hypertension with comp./secondary hypertension 106 4.2 241 2.4 1.66 (1.17-2.35) 
Hypertensive heart and/or renal disease 90 3.5 213 2.1 1.60 (1.10-2.33) 
Cerebrovascular disease 145 5.5 560 5.3 1.02 (0.78-1.33) 
Acute cerebrovascular disease 56 2.2 212 2.1 1.17 (0.77-1.80) 
Occlusion of cerebral arteries 32 1.2 125 1.2 1.04 (0.59-1.81) 
Occlusion or stenosis of precerebral arteries 27 1.0 127 1.2 0.77 (0.42-1.41) 
Transient cerebral ischemia 35 1.4 149 1.5 0.81 (0.47-1.37) 
  5-10 Years 
 Survivors General Population  
  n % n % HR 99% CI 
Hypertension 874 33.0 2,906 27.7 1.44 (1.28-1.62) 
Essential hypertension 137 14.2 814 13.5 0.96 (0.70-1.32) 
Hypertension with comp./secondary hypertension 101 4.2 241 2.4 1.65 (1.15-2.37) 
Hypertensive heart and/or renal disease 95 3.9 218 2.2 1.80 (1.24-2.63) 
Cerebrovascular disease 124 4.7 494 4.7 1.27 (0.94-1.70) 
Acute cerebrovascular disease 47 1.9 203 2.0 1.20 (0.75-1.92) 
Occlusion of cerebral arteries 32 1.7 101 1.3 1.19 (0.67-2.12) 
Occlusion or stenosis of precerebral arteries 26 1.0 112 1.1 1.09 (0.56-2.13) 






Table 2.4: Circulatory system disease risks at 1-5 and >5-10 years after diagnosis among endometrial cancer survivors in comparison to a 































  1-5 Years 
 Survivors General Population  
  n % n % HR 99% CI 
Diseases of arteries; arterioles; and capillaries 495 18.7 1,366 13.0 1.44 (1.24-1.68) 
Peripheral and visceral atherosclerosis 108 4.2 256 2.5 1.77 (1.27-2.48) 
Atherosclerosis of arteries of extremities 17 0.6 52 0.5 1.75 (0.76-4.02) 
Peripheral vascular disease unspecified 39 1.5 103 1.0 1.75 (1.01-3.01) 
Other peripheral and visceral atherosclerosis 70 2.7 163 1.6 1.69 (1.12-2.56) 
Aortic; peripheral; and visceral artery aneurysms 17 0.7 63 0.6 1.15 (0.53-2.50) 
Aortic and peripheral arterial embolism or thrombosis 10 0.4 24 0.2 1.73* (0.59-5.10) 
Other circulatory disease 262 12.7 779 8.4 1.47 (1.19-1.83) 
Hypotension 99 3.9 237 2.3 1.85 (1.29-2.65) 
Other and unspecified circulatory disease 223 10.5 681 7.3 1.33 (1.06-1.68) 
Diseases of veins and lymphatics 615 23.2 1,380 13.1 1.86* (1.62-2.14) 
Phlebitis; thrombophlebitis and thromboembolism 134 5.7 248 2.5 2.24* (1.63-3.08) 
Phlebitis and thrombophlebitis 53 2.1 82 0.8 3.11 (1.83-5.28) 
Other venous embolism and thrombosis 124 5.2 225 2.2 2.19* (1.57-3.05) 
Hemorrhoids 206 9.1 680 7.4 1.26 (1.00-1.58) 






Table 2.4 Continued 
 
Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race. The following outcomes were evaluated but no elevated risk 
was observed: abdominal aortic aneurysm; without rupture, other aneurysm, arterial embolism and thrombosis of lower extremity artery, other 
arterial embolism and thrombosis, varicose veins of lower extremity. 
  




 5-10 Years  
 Survivors General Population   
 n % n % HR 99% CI 
Diseases of arteries; arterioles; and capillaries 372 14.1 1,244 11.8 1.44 (1.21-1.73) 
Peripheral and visceral atherosclerosis 64 2.6 233 2.3 1.59 (1.04-2.44) 
Atherosclerosis of arteries of extremities 14 0.5 37 0.4 1.76 (0.63-4.89) 
Peripheral vascular disease unspecified 22 0.9 93 0.9 1.16 (0.57-2.36) 
Other peripheral and visceral atherosclerosis 46 1.8 161 1.6 1.63 (0.99-2.69) 
Aortic; peripheral; and visceral artery aneurysms 12 0.5 61 0.6 1.23 (0.46-3.29) 
Aortic and peripheral arterial embolism or thrombosis 7 0.3 20 0.2 1.53 (0.45-5.23) 
Other circulatory disease 175 9.7 671 7.9 1.36 (1.04-1.77) 
Hypotension 73 3.0 227 2.3 1.51 (1.01-2.26) 
Other and unspecified circulatory disease 144 7.6 593 6.8 1.22* (0.92-1.63) 
Diseases of veins and lymphatics 380 14.4 1,098 10.5 1.60 (1.35-1.91) 
Phlebitis; thrombophlebitis and thromboembolism 64 2.9 205 2.1 1.61 (1.05-2.48) 
Phlebitis and thrombophlebitis 18 0.7 64 0.6 1.92 (0.84-4.38) 
Other venous embolism and thrombosis 55 2.4 183 1.9 1.40 (0.88-2.23) 
Hemorrhoids 125 6.0 481 5.7 1.25 (0.93-1.68) 






Table 2.5: Heart disease risk at 1-5 and >5-10 years after diagnosis among endometrial cancer survivors in comparison to a general population 
cohort of women.   
 
  
  1-5 Years 
 Survivors General Population  
  n % n % HR 99% CI 
Diseases of the heart 962 36.3 2,742 26.1 1.44 (1.29-1.61) 
Heart valve disorders 129 5.5 425 4.3 1.19 (0.88-1.60) 
Peri-; endo-; and myocarditis; cardiomyopathy 48 1.9 157 1.5 1.23 (0.76-2.01) 
Cardiomyopathy 28 1.1 104 1.0 0.99 (0.54-1.85) 
Other peri-; endo-; and myocarditis 25 1.9 69 0.7 2.11 (1.02-4.37) 
Acute myocardial infarction 41 1.6 113 1.1 1.50 (0.87-2.58) 
Coronary atherosclerosis and other heart disease 130 5.5 454 4.7 1.32* (0.98-1.77) 
Angina pectoris 27 1.1 114 1.1 0.70 (0.37-1.33) 
Coronary atherosclerosis 114 4.7 381 3.9 1.27 (0.93-1.75) 
Nonspecific chest pain 222 10.6 724 8.3 1.26 (1.00-1.57) 
Pulmonary heart disease 130 5.3 266 2.6 1.71 (1.24-2.36) 
Other and ill-defined heart disease 113 4.6 319 3.1 1.23 (0.89-1.71) 
Conduction disorders 62 2.5 204 2.0 1.29 (0.83-1.99) 
Cardiac dysrhythmias 225 10.8 704 7.7 1.51 (1.19-1.90) 
Paroxysmal supraventricular tachycardia 16 0.6 57 0.6 1.11 (0.49-2.47) 
Paroxysmal ventricular tachycardia 17 0.7 46 0.4 2.18 (0.83-5.72) 
Atrial fibrillation 101 4.1 295 2.9 1.44 (1.02-2.02) 
Atrial flutter 28 1.1 70 0.7 1.44 (0.75-2.77) 
Premature beats 49 1.9 142 1.4 1.54 (0.94-2.54) 
Other cardiac dysrhythmias 194 8.7 566 6.0 1.50 (1.17-1.92) 
Cardiac arrest and ventricular fibrillation 17 0.7 47 0.5 1.99 (0.81-4.88) 
Congestive heart failure; nonhypertensive 127 5.2 382 3.8 1.43 (1.06-1.95) 






Table 2.5 Continued 
Models adjusted for  baseline BMI, baseline Charlson Comorbidity Index, and race. 
*Models in violation of the proportional hazards assumption that were evaluated using flexible parametric survival models with restricted cubic 
splines 
 >5-10 Years 
 Survivors General Population  
 n % n % HR 99% CI 
Diseases of the heart 680 25.7 2,275 21.7 1.50 (1.31-1.71) 
Heart valve disorders 100 4.5 346 3.7 1.43 (1.02-2.03) 
sPeri-; endo-; and myocarditis; cardiomyopathy 44 1.7 123 1.2 1.63 (0.94-2.80) 
Cardiomyopathy 31 1.2 91 0.9 1.48 (0.75-2.90) 
Other peri-; endo-; and myocarditis 20 0.8 41 0.4 2.61 (1.12-6.07) 
Acute myocardial infarction 26 1.0 104 1.0 0.98 (0.48-2.00) 
Coronary atherosclerosis and other heart disease 98 4.4 367 4.0 1.09 (0.75-1.57) 
Angina pectoris 34 1.3 99 1.0 1.19 (0.62-2.30) 
Coronary atherosclerosis 85 3.6 298 3.1 1.13 (0.75-1.69) 
Nonspecific chest pain 131 7.0 527 6.6 1.24 (0.92-1.67) 
Pulmonary heart disease 63 2.7 245 2.5 1.26 (0.83-1.92) 
Other and ill-defined heart disease 97 4.2 293 3.0 1.47* (1.01-2.13) 
Conduction disorders 48 1.9 208 2.1 1.05 (0.64-1.73) 
Cardiac dysrhythmias 160 8.6 572 6.8 1.53 (1.16-2.04) 
Paroxysmal supraventricular tachycardia 11 0.4 37 0.4 0.92 (0.30-2.81) 
Paroxysmal ventricular tachycardia 17 0.7 54 0.5 1.49 (0.64-3.49) 
Atrial fibrillation 75 3.2 296 3.0 1.25 (0.85-1.84) 
Atrial flutter 24 0.9 78 0.8 1.26 (0.61-2.57) 
Premature beats 36 1.4 123 1.2 1.92 (1.06-3.48) 
Other cardiac dysrhythmias 142 6.0 444 5.0 1.76 (1.31-2.37) 
Cardiac arrest and ventricular fibrillation 16 0.6 49 0.5 1.38 (0.57-3.38) 
Congestive heart failure; nonhypertensive 100 4.3 326 3.4 1.58 (1.08-2.31) 




Table 2.6: Risk factor for hypertension, heart disease, and vascular diseases among 
endometrial cancer survivors  
  Hypertension 
  1-5 Years >5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea  
Surgery only Reference 
Surgery and radiation 1.14 (1.00-1.30) 1.1 (0.93-1.29) 
Surgery and chemotherapy 1.27 (0.90-1.80) 1.26 (0.67-2.36) 
Surgery, radiation, and chemotherapy 1.18 (0.89-1.55) 1.19 (0.79-1.77) 
Stageb     
Local Reference 
Regional 1.02 (0.88-1.19) 1.07 (0.88-1.30) 
Advanced 0.93 (0.64-1.36) 0.73 (0.30-1.77) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  0.95 (0.84-1.08) 0.94 (0.82-1.09) 
Grade III (Poorly differentiated) 1.05 (0.89-1.23) 0.79 (0.63-0.99) 
Grade IV (Undifferentiated) 1.10 (0.74-1.63) 0.71 (0.33-1.49) 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.27 (1.08-1.51) 1.17 (0.99-1.39) 
2005-2010 1.18 (1.02-1.38) 0.84 (0.70-0.99) 
2011-2012 1.08 (0.88-1.33) . . 
Age at Diagnosisd     
<50 Reference 
50-59 1.64 (1.32-2.03) 1.67 (1.32-2.11) 
60-69 2.31 (1.87-2.85) 2.27 (1.80-2.86) 
70-79 2.84 (2.27-3.55) 2.63 (2.04-3.39) 
80+ 3.42 (2.64-4.43) 3.26 (2.36-4.51) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.52 (1.32-1.76) 1.73 (1.47-2.05) 
2+ 2.78 (2.41-3.20) 2.82 (2.36-3.37) 
Baseline BMIf     
<18 kg/m2 1.02 (0.45-2.29) 1.72 (0.76-3.90) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.69 (1.43-2.00) 1.46 (1.20-1.78) 





Table 2.6 Continued 
  Heart Disease 
  1-5 Years >5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.12 (0.96-1.30) 1.08 (0.90-1.29) 
Surgery and chemotherapy 2.29 (1.62-3.23) 1.32 (0.65-2.66) 
Surgery, radiation, and chemotherapy 1.91 (1.44-2.54) 1.19 (0.75-1.90) 
Stageb     
Local Reference 
Regional 1.02 (0.88-1.19) 1.06 (0.85-1.33) 
Advanced 0.93 (0.64-1.36) 2.10 (1.03-4.26) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.06 (0.92-1.23) 1.05 (0.89-1.24) 
Grade III (Poorly differentiated) 1.56 (1.31-1.86) 1.00 (0.78-1.28) 
Grade IV (Undifferentiated) 2.35 (1.63-3.40) 0.62 (0.25-1.49) 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.02 (0.85-1.23) 0.96 (0.79-1.16) 
2005-2010 0.89 (0.75-1.05) 0.72 (0.59-0.87) 
2011-2012 0.70 (0.55-0.89) . . 
Age at Diagnosisd     
<50 Reference 
50-59 1.44 (1.13-1.84) 1.41 (1.08-1.83) 
60-69 1.99 (1.57-2.53) 1.86 (1.44-2.41) 
70-79 2.65 (2.06-3.39) 2.40 (1.81-3.18) 
80+ 4.01 (3.03-5.30) 3.92 (2.79-5.49) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.75 (1.48-2.06) 1.71 (1.41-2.07) 
2+ 3.05 (2.61-3.57) 3.13 (2.57-3.81) 
Baseline BMIf     
<18 kg/m2 0.67 (0.25-1.81) 0.86 (0.27-2.69) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.26 (1.06-1.51) 1.27 (1.02-1.57) 






Table 2.6 Continued 
  Diseases of the Arteries 
  1-5 Years >5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea  
Surgery only Reference 
Surgery and radiation 1.26 (1.02-1.56) 1.10 (0.86-1.41) 
Surgery and chemotherapy 3.19 (2.10-4.85) 1.56 (0.64-3.81) 
Surgery, radiation, and chemotherapy 1.99 (1.36-2.92) 1.23 (0.67-2.26) 
Stageb     
Local Reference 
Regional 1.18 (0.94-1.50) 1.09 (0.81-1.47) 
Advanced 2.90 (1.91-4.41) 1.46 (0.53-4.00) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.22 (0.99-1.50) 1.02 (0.82-1.28) 
Grade III (Poorly differentiated) 1.82 (1.43-2.32) 1.03 (0.74-1.43) 
Grade IV (Undifferentiated) 2.97 (1.87-4.73) 0.48 (0.12-1.96) 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.11 (0.85-1.46) 1.03 (0.79-1.33) 
2005-2010 1.14 (0.90-1.45) 0.86 (0.66-1.12) 
2011-2012 1.08 (0.78-1.50) . . 
Age at Diagnosisd     
<50 Reference 
50-59 1.50 (1.06-2.12) 1.52 (1.05-2.19) 
60-69 1.77 (1.26-2.50) 1.98 (1.38-2.84) 
70-79 2.66 (1.87-3.78) 2.28 (1.55-3.37) 
80+ 3.62 (2.45-5.37) 2.13 (1.28-3.54) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.84 (1.46-2.32) 2.2 (1.70-2.83) 
2+ 2.96 (2.37-3.68) 3.81 (2.92-4.96) 
BMIf     
<18 kg/m2 0.75 (0.18-3.04) 2.25 (0.82-6.15) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.17 (0.91-1.52) 1.29 (0.98-1.70) 






Table 2.6 Continued 
  Diseases of the Veins/Lymphatics 
  1-5 Years >5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.29 (1.06-1.56) 1.12 (0.88-1.44) 
Surgery and chemotherapy 2.16 (1.44-3.24) 1.30 (0.54-3.16) 
Surgery, radiation, and chemotherapy 2.29 (1.67-3.14) 1.13 (0.63-2.03) 
Stageb     
Local Reference 
Regional 1.34 (1.09-1.65) 1.22 (0.92-1.63) 
Advanced 3.11 (2.15-4.48) 1.67 (0.68-4.09) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.19 (1.00-1.43) 1.16 (0.94-1.45) 
Grade III (Poorly differentiated) 1.67 (1.34-2.08) 0.94 (0.67-1.33) 
Grade IV (Undifferentiated) 1.89 (1.16-3.09) 0.24 (0.03-1.75) 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 0.97 (0.76-1.24) 1.02 (0.79-1.32) 
2005-2010 1.28 (1.04-1.59) 0.94 (0.73-1.22) 
2011-2012 0.95 (0.70-1.28) . . 
Age at Diagnosisd     
<50 Reference 
50-59 1.31 (1.01-1.70) 1.06 (0.79-1.42) 
60-69 1.34 (1.03-1.74) 1.00 (0.73-1.35) 
70-79 1.41 (1.05-1.89) 1.03 (0.72-1.48) 
80+ 1.28 (0.88-1.87) 0.59 (0.32-1.08) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.12 (0.91-1.38) 1.68 (1.31-2.14) 
2+ 1.47 (1.19-1.80) 1.90 (1.43-2.52) 
BMIf     
<18 kg/m2 0.49 (0.12-1.98) 2.41 (0.97-5.98) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.00 (0.80-1.25) 1.27 (0.95-1.70) 
>30 kg/m2 1.19 (0.97-1.46) 1.28 (0.97-1.68) 
 
Models adjusted for a. Charlson Comorbidity Index, BMI, race, year of diagnosis, and age at 
diagnosis; b.histology, age at diagnosis, diagnosis year, BMI, Charlson Comorbidity Index, Race; 
c. BMI, Charlson Comorbidity Index, race, endometrial cancer type; d. BMI, race, diagnosis year, 
Charlson Comorbidity Index, stage, histology; e.,age at diagnosis, diagnosis year, race; f. 














With an estimated 757,000 survivors in 2016, endometrial cancer is the second most 
common cancer among female cancer survivors in the United States. Endometrial cancer 
survivors are at increased risk for various adverse genitourinary outcomes. Because of the large 
number of survivors in the United States as well as the high overall survival rate among 
endometrial cancer survivors, investigations of long-term adverse health outcomes in proximal 
bodily regions (such as the genitourinary system) are likely to be affected by disease, treatment, 
and other comorbidities are important for the management and surveillance of these outcomes 
among endometrial cancer survivors. 
Cohorts of 2,648 endometrial cancer survivors diagnosed in the state of Utah between 
1997 and 2012, and 10,503 age-matched women from the general population were identified 
using the Utah Population Database. All ICD-9 diagnosis codes were collected from the state’s 
two largest healthcare systems and statewide ambulatory surgery and inpatient visits. 
Multivariate Cox regression models were used to estimate hazard ratios (HR) at 1-5 years and 




Endometrial cancer survivors were at elevated risk for urinary system disorders between 
1-5 years (HR: 1.64, 99% CI: 1.47-1.83) and >5-10 years (HR: 1.40, 99% CI: 1.22-1.61) and genital 
organ disorders between 1-5 years (HR: 1.71, 99% CI: 1.54-1.91) and >5-10 years (HR: 1.33, 99% 
CI: 1.15-1.54). The highest risks among endometrial cancer survivors were observed between 1-
5 years for hydronephrosis (HR: 5.74, 99% CI: 3.40-9.69), nephritis, nephrosis, and renal sclerosis 
(HR: 3.53, 99% CI: 1.85-6.74), calculus of the kidneys (HR: 2.97, 99% CI: 1.74-5.08), and acute 
and unspecified renal failure (HR: 2.21, 99% CI: 1.60-3.06). Between 1-5 years after cancer 
diagnosis, elevated risk for urinary disorders was observed among cancer survivors who were 
treated with different combinations of radiation therapy, chemotherapy, and/or surgery 
compared to those who received surgery alone.  
Endometrial cancer survivors in this population were at higher risk for genitourinary 
outcomes compared to women from the general population in the state of Utah, especially 
between 1 and 5 years after cancer diagnosis. This study presents evidence to suggest that 
increased monitoring for diseases of the genitourinary system is necessary for women 




In the United States, endometrial cancer is the second most common cancer among 
female cancer survivors, the fourth most commonly diagnosed cancer among women, and the 
tenth most commonly diagnosed cancer overall.1 Since 1988, Incidence rates for women under 
the age of 50 have increased by 1.3% per year and by 1.9% per year among women over the age 
of 50 since 2005.2 The mortality rate due to endometrial cancer has increased by 1.1% each year 




the United States, which increased to 635,437 in 2013, and it is projected that there were 
757,000 endometrial cancer survivors in 2016.3,4 The current 5-year survival rate in the United 
States is 81.7% for endometrial cancer overall, 95.3% for women diagnosed with stage I disease, 
68.2% in women diagnosed with stage II and III disease, and 16.9% for women diagnosed with 
IV.2 
A wide range of acute and long-term adverse genitourinary outcomes that are often 
directly related to treatment with surgery and/or radiotherapy have been observed among 
endometrial cancer survivors. Following treatment with radiation therapy therapy, long-term 
damage to the genital organs has been well documented.8,9 radiation therapy can induce 
damage to connective tissue of the vagina, chronic vaginal discharge, necrosis, ulceration, fistula 
formation, thinning and atrophy of the vaginal epithelium, fibrosis, loss of elasticity of the 
vagina have also been observed. Individuals treated with external beam radiation therapy suffer 
chronic bony pain secondary to hip fracture that affects locomotion.10  After abdominal surgery 
patients are at increased risk for a bowel obstruction and this is increased with external beam 
radiation therapy. 
In a study that measured short term vaginal and urinary toxicity due to interstitial 
brachytherapy for locally advanced endometrial, cervical, vulvar, or vaginal cancer, 17.8% of the 
population experienced grade 3 vaginal toxicity and 15.1% experienced grade 3 urinary toxicity 
within 1 year, resulting in symptoms that can persist more than a year after the completion of 
treatment.11 While this study suggests that grade 3 vaginal and urinary toxicity are likely to 
occur in individuals treated with interstitial brachytherapy, no patients experienced grade 4 or 5 
toxicity. Both vaginal and urinary toxicity may contribute to many of the adverse genitourinary 





In a prospective study of individuals diagnosed with endometrial cancer, 30% had 
urinary complications, 9.2% had genital complications, and 2.3% had pelvic soft tissue 
complications within 1 year after diagnosis.12 In this population, a higher proportion of 
individuals treated with surgery alone reported urinary complications than those treated with 
surgery and radiation therapy, surgery and chemotherapy, and surgery, radiation therapy, and 
chemotherapy. After 5 years postdiagnosis, urinary symptoms remained the most common.  
Urinary incontinence is one of the most common long-term effects among endometrial 
cancer survivors.13-21 In a comparison of urinary incontinence among survivors of several 
different cancer types, 40.2% of endometrial cancer survivors experienced urinary incontinence, 
which was higher than any of the other cancers examined (breast, prostate, bladder, colorectal, 
and lung), which ranged from 27.1%-35.2%.13 Long-term stress urinary incontinence and voiding 
dysfunction have also been observed to be higher among endometrial cancer survivors treated 
with radical hysterectomy compared to total abdominal hysterectomy16 and in women treated 
with radiation therapy compared to surgery alone.17 However, in a comparison of adverse 
urinary outcomes between recurrence-free survivors of gynecologic cancers and controls from 
the general population, no elevated risk was observed among those treated with radiation 
therapy.22 
Survivors of endometrial and cervical cancer also experience urinary urgency, daytime 
leakage at least once a day, bladder pain, and nocturia. They are 2-5 times more likely to 
experience symptoms of urinary incontinence after 1 year of treatment cessation.18 Endometrial 
cancer patients treated with external beam radiation therapy were at higher risk for urinary 
incontinence compared to those treated with brachytherapy at 7 and 10 years after diagnosis.19 
Additionally, there is evidence that the combination of external beam radiation therapy and 




radiation therapy or brachytherapy alone.20  
Long-term surveillance of surgically treated patients has suggested that regional 
complications due to surgery are usually resolved within 1 year, while treatment with radiation 
therapy can cause damage to tissue architecture of the genital and urinary systems that can 
persist for years after treatment cessation.21,23  
Many prior investigations of genitourinary outcomes among endometrial cancer 
survivors have often lack objective measures to capture outcomes, examine symptoms that are 
secondary to more clinically relevant genitourinary conditions, or are conducted using small 
sample sizes. Large cohort studies that are sufficiently powered to examine a large number of 
genitourinary outcomes from reliable sources such as electronic medical records that have a 
detrimental effect on quality of life and mortality are necessary to better understand the 
experience of endometrial cancer survivors years after diagnosis. Thus, the goal of the current 
study was to examine the risk for long-term, adverse genitourinary diseases among endometrial 
cancer survivors compared to the general population. 
 
3.3 Methods 
3.3.1 Data Collection 
An initial cohort of 3,624 endometrial cancer survivors was identified using the Utah 
Population Database.  Diagnosis data were available from the statewide SEER Utah Cancer 
Registry for women aged 18 and over, diagnosed with invasive first primary endometrial cancer 
between 1997 and 2012 in the state of Utah (SEER ICD-O-3 codes: C54.0-C55.9). Endometrial 
cancer histological subtypes adenocarcinoma, endometrioid, mucinous adenocarcinoma, and 
adenocarcinoma with squamous differentiation were classified as Type I (ICD-O-3 morphology 




papillary serous carcinomas as type II (ICD-O-3 morphology codes: 8310, 8441, and 8460).24 
Eligible survivors were required to have stage and grade included in diagnosis records from the 
Utah Cancer Registry and to have lived in the state of Utah for at least 1 year after diagnosis. 
Survivors were matched with up to 5 women from the general population on birth year and 
birth state. 
Outcome data used for this study included statewide ambulatory and inpatient data 
from the Utah Department of Health and Electronic Data Warehouse data from Intermountain 
Health Care and the University of Utah Health Sciences Center. The Utah Population Database 
data included records from the Utah Cancer Registry, Utah Driver’s License, vital records, and 
the Utah Department of Health. Statewide ambulatory and inpatient records as well as those 
from the University of Utah and Intermountain Healthcare systems were linked via the Utah 
Population Database.  
Electronic medical record data was available prior to 1992, but all three major sources 
did not have comprehensive electronic medical record data for individuals in these cohorts until 
1996. Individuals diagnosed with endometrial cancer between 1997 and 2012 were included in 
this analysis to allow adequate time prior to cancer diagnosis to capture prior diagnoses of the 
genitourinary outcomes of interest. A total of 153 endometrial cancer patients were excluded 
because their cancer was not staged, 470 because grade was missing, 285 because follow up 
time did not exceed 1 year, 65 because their Utah residence did not exceed 1 year. The stage 
and grade were necessary for our sample because we were interested in their potential role in 
risk for the outcomes measured in this study. There were a total of 2,648 endometrial cancer 






3.3.2 Categorization of Outcomes 
Outcome data from the statewide, University of Utah Health Sciences Center, and 
Intermountain Healthcare systems included all available ICD-9 diagnosis codes, as well as 
diagnosis date which allowed for time to outcome to be calculated. The Clinical Classification 
Software developed by the Health Cost and Utilization Project was used to categorize ICD-9 
codes into 4 levels of specificity (Levels 1-4).25 Diseases of the genitourinary system (level 1) 
according to the Clinical Classification Software were used in this analysis. Level 2 outcomes 
included diseases of the urinary system and disease of the genital organs. More specific 
outcomes within these categories were analyzed as level 3 and 4 outcomes. Examples of this 
hierarchy include diseases of the urinary system (level 2), acute and unspecified renal failure 
(level 3), acute renal failure (level 4).  
Long-term genitourinary outcomes were measured at 1-5 years and >5-10 years after 
endometrial cancer diagnosis. Follow-up time for incident cases of each outcome was calculated 
separately from the endometrial cancer survivor’s initial cancer diagnosis to the date of 
diagnosis for each outcome, last date of follow-up, or date of death. Individuals who did not 
have that outcome were censored at the date of last follow-up (last residence date in Utah or 
death) if that date fell within the analysis time period (1-5 years or >5-10 years) or at the end of 
each analysis time period if their date of last-follow-up exceeded the end of the analysis time 
period. Levels 3 or 4 outcomes diagnosed prior to the start of each analysis time period were 
considered prevalent cases of those outcomes and were excluded from the models.  Level 1 and 







3.3.3 Statistical Analysis  
Chi-square tests were used to compare baseline characteristics between the 
endometrial cancer survivors and general population cohorts. Univariate and multivariate Cox 
proportional hazard models were used to calculate hazard ratios for long-term genitourinary 
outcomes at 1-5 years and >5-10 years after endometrial cancer diagnosis. We used 99% 
confidence intervals to account for the penalty imposed by multiple testing due to the large 
number of outcomes examined in this analysis. Multivariate models were adjusted for matching 
factors, baseline body mass index (BMI), baseline Charlson Comorbidity Index,26 and race. Cox 
proportional hazard models were also used to investigate risk factors such as treatment type, 
stage, grade, age at diagnosis, year of diagnosis, race, BMI, and rural/urban residence for 
hypertension, heart disease, diseases of the arteries, arterioles, and capillaries, and diseases of 
the veins and lymphatics among endometrial cancer survivors. The proportional hazards 
assumption was checked for each model using a test for nonzero slope of the Schoenfeld 
residuals vs time. Models that were in violation of the proportional hazards assumption were 
then tested with flexible parametric survival models with restricted cubic splines. Hazard ratios 
from the Cox proportional hazard models were reported where there were no substantive 
differences. 
Baseline BMI values at least 1 year prior to cancer survivors’ endometrial cancer 
diagnosis were calculated from the driver’s license records.  For the cancer-free women, the 
most recent BMI value recorded at least 1 year prior to the endometrial cancer diagnosis date of 
the matched cancer patient was included. Approximately 35% of the survivors cohort and 39% 
of the general population cohort were missing baseline BMI. For individuals missing BMI, BMI 
values were imputed using a linear regression model with 10 imputations that included cancer 




covariates. Models were run with and without the imputed values to assure that the inferences 
did not change due to the imputation of BMI (data not shown).  
 
3.4 Results 
The endometrial cancer survivors cohort had a higher proportion of obese individuals 
(44.2% vs 19.2%) than the general population cohort (p<0.001, Table 3.1). A higher proportion 
of individuals diagnosed with endometrial cancer (27.3%) were deceased compared to 15.2% in 
the general population cohort (p<0.001). Nearly 81.5% of the endometrial cancer survivors were 
diagnosed with grade I or II and 80.3% with stage I disease (Table 3.2). The majority (86.9%) 
were diagnosed with type I endometrial cancer, 3.3% with type II, and 9.9% were unknown. 
Among endometrial cancer survivors, 68.5% were treated with surgery alone, 21.9% with 
surgery and radiation therapy, 3.2% with surgery and chemotherapy, and 4.7% with surgery, 
radiation therapy, and chemotherapy.  The mean follow-up time among survivors is 8.5 years. 
Approximately 27% have total follow-up time between 1-5 years, 39% between >5-10 years, and 
34% in excess of 10 years. 
Between 1-5 years after cancer diagnosis, elevated risk for urinary system disorders was 
observed among cancer survivors for 20 out of 23 outcomes that were investigated (Table 3.3). 
More than 37% of survivors were diagnosed with a urinary system disorder compared to 24% of 
the general population during this time period. Elevated risk persisted between >5-10 years 
after diagnosis for 13 of those outcomes. Higher risk for diseases of the kidneys (including 
nephritis, nephrosis, renal sclerosis, and acute renal failure) and urinary tract infections (cystitis 
and urethritis and urinary tract infections of unspecified site) among endometrial cancer 
survivors were observed between both 1-5 and >5-10 years after diagnosis. The highest risk 




99% CI: 3.40-9.69). After 5 years, endometrial cancer patients were 2.4 times more likely to be 
diagnosed with hydronephrosis (99% CI: 1.22-4.73). Survivors were 2-3 times more likely to be 
diagnosed with calculus of the kidneys or ureters, other diseases of the bladder and urethra, and 
other and ill-defined genitourinary symptoms between 1-5 years but not between >5-10 years. 
Survivors were at higher risk for chronic kidney disease at 1-5 years but not at >5-10 years after 
diagnosis. 
Between 1-5 years after diagnosis, 36.9% of survivors were diagnosed with a genital 
organ disorder compared to 26.2% of individuals in the general population (Table 3.4). Survivors 
were at elevated risk of genital organ disorders overall at both 1-5 years (HR: 1.71, 99% CI: 1.54-
1.91) and at >5-10 years (HR: 1.33, 99% CI: 1.15-1.54). Additionally, endometrial cancer survivors 
were at higher risk for nonmalignant breast conditions, inflammatory diseases of the pelvic 
organs, other genital disorders, and genital pain and other symptoms between 1-5 years. 
Elevated risk continued at >5-10 years after diagnosis only for nonmalignant breast conditions. 
Individuals treated with surgery in combination with radiation therapy and/or 
chemotherapy were at higher risk for both urinary system and genital organ disorders compared 
to those treated with surgery alone at 1-5 years after diagnosis but not at >5-10 years, with the 
exception of those treated with surgery and radiation therapy for urinary system disorders. 
Individuals diagnosed with regionally advanced disease were at elevated risk for urinary system 
disorders compared to those with localized disease at both 1-5 and >5-10 years after diagnosis. 
Stage at diagnosis was not associated with risk for genital organ disorders at either 1-5 or >5-10 
years after diagnosis. Higher grade endometrial cancers were associated with elevated risk for 
urinary system disorders compared to grade I cancers at 1-5 years but not >5-10 years after 
diagnosis. Individuals diagnosed with stage IV disease were at higher risk of genital organ 




endometrial cancer survivors, higher BMI was not associated with urinary system or genital 
organ disorders. Figure 3.1 shows the cumulative incidence of select genitourinary outcomes 
between cancer survivors and individuals from the general population. 
 
3.5 Discussion 
These results present an important addition to the body of literature concerning long-
term, adverse genitourinary outcomes among endometrial cancer survivors. The majority of 
investigations into these associations have focused on urinary and genital symptoms that affect 
health-related quality of life among survivors that were measured using self-report from 
patients. This is the first large cohort study to compare all available genitourinary outcomes 
from electronic medical record data between endometrial cancer survivors and matched 
individuals from the general population. This analysis supports many of the findings of prior 
investigations by showing an association between endometrial cancer diagnosis and several of 
the underlying conditions that might result in urinary incontinence, daytime leakage, nocturia, 
voiding difficulty, and bladder, genital, and pelvic pain. In this population, endometrial cancer 
survivors were at elevated risk for both urinary system and genital organ disorders between 1-5 
and >5-10 years after diagnosis. These results also provide evidence that those treated with 
radiation therapy and/or chemotherapy compared to those treated with surgery alone are at 
higher risk for both urinary system and genital organ disorders within 5 years of diagnosis.  
Endometrial cancer survivors were 64% more likely to be diagnosed with a urinary 
system disorder between 1-5 years and 40% more likely between >5-10 years compared to 
individuals in the general population. The majority of studies that have examined urinary system 
disorders due to cancer treatment in women have focused on cervical cancer.17 Those that have 




mixed results14,17,22 and have largely focused on conditions such as urinary incontinence that 
may be secondary to many of the outcomes that were measured in the study. In this study, 
endometrial cancer survivors were at elevated risk for nearly all of the urinary system disorders 
that were examined at 1-5 years, with risk persisting at >5-10 years for many that have not been 
previously investigated on this scale. Using data from electronic medical records provides a 
more objective measure of these conditions which may not have been captured by patient self-
report or were not previously measured.  
An additional important finding of our study is the elevated risk for a number of renal 
conditions including acute renal failure, chronic kidney disease, calculus of the kidneys, 
hydronephrosis, and nephritis, nephrosis and renal sclerosis. These conditions are often 
associated with obesity and advanced age, which are shared risk factors for endometrial cancer. 
We adjusted for BMI and age at diagnosis and found a significant association between 
endometrial cancer diagnosis and these conditions, while the case-only risk factor analysis 
suggested that elevated BMI was not associated with urinary system disorders overall among 
endometrial cancer survivors compared to those in the normal BMI range prior to endometrial 
cancer diagnosis. However, survivors diagnosed at a later age were more likely to be diagnosed 
with urinary system disorders. Our results suggest that elevated risk for urinary system disorders 
may be the result of radiation therapy and/or chemotoxicity, limited to the 1-5 years after 
diagnosis. This is further supported by the observation that elevated risk for many of the 
outcomes measured was not observed after 5 years since cancer diagnosis, though there is 
evidence that damage to the urinary system related to treatment can cause severe long-term 
renal damage that can result in acute renal failure.  
While we observed elevated risk for genital organ disorders among endometrial cancer 




urinary system disorders, elevated risk for genital organ disorders among those treated with 
radiation therapy and/or chemotherapy compared to those treated with surgery alone was also 
observed only in the 1-5 year period after cancer diagnosis. There was a higher level of 
granularity for urinary system disorders than for genital organ disorders. The level 3 genital 
organ disorders include nonmalignant breast conditions, inflammatory diseases of female pelvic 
organs, endometriosis, prolapse of female genital organs, menstrual disorders, ovarian cyst, 
menopausal disorders, female infertility, and other female genital disorders. Only two of these 
categories contain more specific diagnoses and include a category of “other” which may include 
disparate conditions. Further, several of these are of no relevance in individuals who have 
undergone hysterectomy or bilateral salpingo-oophorectomy, leaving only a few clinically 
meaningful or easily interpretable genital organ outcomes for analysis. Despite this, our results 
support previous findings that risk for pelvic pain and inflammatory diseases of the pelvic organs 
are common among endometrial cancer survivors and we were able to quantify risk for these 
conditions compared to the general population. 
This study has a number of significant strengths. The large sample size (>2,600 
endometrial cancer survivors and >10,500 cancer free women) and use of electronic medical 
record data provides a more objective measure of the experience of endometrial cancer 
survivors with respect to genitourinary outcomes. In addition, the electronic medical record 
data used in this study come from the state’s two largest healthcare systems as well as 
statewide ambulatory surgery and inpatient data, providing a more complete record of the 
medical history of study patients. These data also contain a large amount of follow-up time for 
individuals in both cohorts. The mean follow-up time among survivors is 8.5 years. 
Approximately 27% have total follow-up time between 1 and 5 years, 39% between 5 and 10 




reports of disease which are susceptible to survival bias, our study is less susceptible to survival 
bias because we used long-term health records as the source of disease diagnoses. 
This study also has a number of limitations. While the data used for this study is 
comprised of comprehensive electronic medical record data from the two largest healthcare 
systems in the state, as well as statewide ambulatory surgery and inpatient data, there remains 
the possibility that study participants will have been diagnosed with outcomes of interest to 
these analyses in hospitals and clinics not covered by the data sources. However, approximately 
99.6% of cancer patients and 98.6% of the general population cohort did have records in these 
data sources. Additionally, because 42.7% of individuals in the survivor cohort were diagnosed 
after 2006, the potential to examine risk for these outcomes after 10 years is limited due to lack 
of follow-up time for this proportion of the study population. However, with the Utah 
Population Database as a data source, we are able to update our analysis on a regular basis.  
While data were available to investigate treatment related risk factors among endometrial 
cancer survivors, these data were limited to broad treatment categories and did not include 
potentially informative factors such as radiation therapy type and dosage, specific 
chemotherapy agents, and duration of treatment. However, the treatment data that were 
available did provide evidence that risk for several genitourinary outcomes vary by treatment 
type. 
Future research is necessary to more accurately assess causal relationships between 
treatment for endometrial cancer and the outcomes measured in this study. While the 
mechanisms of damage to the genitourinary system due to surgery, chemotherapy and 
radiation therapy have been investigated more completely for cervical cancer, more studies that 
examine these associations among endometrial cancer survivors are necessary. Further analysis 




electronic medical record data are derived from sources that are constantly updated, this study 
has the potential to examine these outcomes in an increasing number of survivors and over a 
longer period of time as new data are collected. 
In conclusion, endometrial cancer survivors in this cohort were at higher risk for a 
number of long-term genitourinary outcomes. These results present a wide range of outcomes 
encompassing urinary system disorders and genital organ disorders. Many of the conditions 
examined in this study have shared risk factors with endometrial cancer, making it difficult to 
disentangle the effects of the disease or its treatment; but the ability to control for many of 
these risk factors provides a clearer picture than has been previously available. It is clear from 
these results that the survivors of endometrial cancers in this cohort experienced a high burden 
of adverse genitourinary outcomes, especially urinary system disorders. These results suggest 
that increased monitoring for genitourinary disease over long periods of time among 
endometrial cancer survivors is warranted. Further, these result highlight the need to place 
more emphasis on survivorship in addition to shorter-term outcomes that encompass the 
majority of the literature on treatment-related effects. 
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population   
  n=2,648 n=10,503   
  n  % n % p 
Birth Year           
<1920 116 4.4 473 4.5   
1920-1929 310 11.7 1,192 11.4   
1930-1939 541 20.4 2,015 19.2   
1940-1949 787 29.7 3,085 29.4   
1950-1959 591 22.3 2,444 23.3   
>1960 303 11.4 1,294 12.3 0.54 
Race           
White 2,525 95.4 9,617 91.6   
Black 10 0.4 29 0.3   
American 





Asian 277 2.6 19 0.7   
Pacific Islander 60 0.6 48 1.8   
Unknown 14 0.5 409 3.9 <0.001 
Vital Status           
        Alive 1,924 72.7 8,906 84.8   
        Dead 724 27.3 1,597 15.2 <0.001 
Baseline BMI           
        <18 kg/m2 18 0.7 307 2.9   
        18-24.9 kg/m2 645 24.4 4,994 47.6   
        25-29.0 kg/m2 814 30.7 3,190 30.7   
        >30 kg/m2 1,171 44.2 2,012 19.2 <0.001 
Age Attained at the End of 





        <50 161 6.1 697 6.6   
        50-59 389 14.7 1,697 16.2   
        60-69 826 31.2 3,142 29.9   
        70-79 692 26.1 2,637 25.1   
        80-89 442 16.7 1,787 17.0   
        90+ 138 5.2 543 5.2 0.303 
Follow up Period           
        1-5 years 726 27.4 2,742 26.1   
        >5-10 years 1,028 38.8 4,062 38.7   
        >10-15 years 595 22.5 2,576 24.5   







Table 3.2: Clinical characteristics among endometrial cancer survivors 
Endometrial Cancer (n=2,648) 
Diagnosis Year n % 
        1997-2000 563 21.26 
        2001-2003 471 17.79 
        2004-2006 483 18.24 
        2007-2009 572 21.60 
        2010-2012 559 21.11 
Age at Diagnosis     
        <40 140 5.29 
        40-49 307 11.59 
        50-59 786 29.68 
        60-69 758 28.63 
        70-79 451 17.03 
        80+ 206 7.78 
Grade     
        Grade I (Well differentiated)  1,314 49.62 
        Grade II (Moderately differentiated)  845 31.91 
        Grade III (Poorly differentiated) 421 15.90 
        Grade IV (Undifferentiated) 68 2.57 
Stage     
        Local 10,565 80.34 
        Regional 2,154 16.38 
        Advanced 432 3.28 
Histology     
        Endometrioid adenocarcinoma 1,853 69.98 
        Adenocarcinoma with squamous differentiation 56 2.11 
        Serous adenocarcinoma 87 3.29 
        Clear cell adenocarcinoma 17 0.64 
        Mixed cell adenocarcinoma 47 1.77 
        Mucinous adenocarcinoma 45 1.70 
        Carcinosarcoma 26 0.98 
        Stromal sarcoma 44 1.66 
        Leiomyosarcoma 41 1.55 
        Other 432 16.31 
Endometrial Cancer Type     
        Type I 2,300 86.86 
        Type II 87 3.29 
        Unknown 261 9.86 
Treatment Type   
        Surgery only 1,813 68.47 
        Surgery and radiation 579 21.87 
        Surgery and chemotherapy 84 3.17 
        Surgery, radiation, and chemotherapy 124 4.68 





Table 3.3:  Urinary system disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in comparison to a 




  1-5 Years 
  Survivors General Population   
Outcome n % n % HR 99% CI 
Diseases of the urinary system 991 37.4 2,572 24.5 1.64* (1.47-1.83) 
Nephritis; nephrosis; renal sclerosis 46 1.7 52 0.5 3.53 (1.85-6.74) 
Acute and unspecified renal failure 139 5.3 249 2.4 2.21 (1.60-3.06) 
Acute renal failure 112 4.2 219 2.1 2.04 (1.42-2.93) 
Unspecified renal failure 50 1.9 81 0.8 2.52 (1.43-4.44) 
Chronic kidney disease 104 3.9 218 2.1 1.78 (1.25-2.54) 
Urinary tract infections 268 10.1 831 7.9 1.52 (1.23-1.88) 
Infections of kidney 41 1.6 135 1.3 1.14 (0.68-1.90) 
Cystitis and urethritis 51 1.9 121 1.2 1.79 (1.12-2.85) 
Urinary tract infection; site not specified 252 9.5 800 7.6 1.50 (1.21-1.86) 
Calculus of urinary tract 76 2.9 140 1.3 1.95 (1.30-2.94) 
Calculus of kidney 52 2.0 79 0.8 2.97 (1.74-5.08) 
Calculus of ureter 38 1.4 62 0.6 1.97 (1.09-3.57) 
Other and unspecified urinary calculus 24 0.9 62 0.6 1.39 (0.73-2.67) 
Other diseases of kidney and ureters 211 8.0 376 3.6 2.25* (1.75-2.90) 
Hydronephrosis 79 3.0 47 0.5 5.74 (3.40-9.69) 
Other diseases of kidney and ureters 196 7.4 360 3.4 2.26* (1.74-2.94) 
Other diseases of bladder and urethra 66 2.5 142 1.4 1.97 (1.27-3.05) 
Other diseases of bladder and urethra 64 2.4 141 1.3 1.93 (1.24-3.01) 
Genitourinary symptoms and ill-defined conditions 248 9.4 811 7.7 1.65 (1.33-2.06) 
Hematuria 102 3.9 204 1.9 2.16 (1.52-3.06) 
Retention of urine 27 1.0 73 0.7 1.16 (0.61-2.22) 









              
Adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race 
*Models in violation of the proportional hazards assumption that were evaluated using flexible parametric survival models with restricted cubic 
splines  
 5-10 Years 
 Survivors General Population  
Outcome n % n % HR 99% CI 
Diseases of the urinary system 638 24.1 2,169 20.7 1.40 (1.22-1.61) 
Nephritis; nephrosis; renal sclerosis 26 1.0 48 0.5 2.84* (1.30-6.22) 
Acute and unspecified renal failure 95 3.6 254 2.4 1.61 (1.12-2.31) 
Acute renal failure 96 3.6 234 2.2 1.82 (1.26-2.63) 
Unspecified renal failure 27 1.0 72 0.7 1.52 (0.76-3.01) 
Chronic kidney disease 88 3.3 257 2.5 1.40 (0.96-2.04) 
Urinary tract infections 177 6.7 678 6.5 1.45 (1.11-1.89) 
Infections of kidney 33 1.3 107 1.0 1.25 (0.68-2.28) 
Cystitis and urethritis 32 1.2 102 1.0 1.83 (1.01-3.33) 
Urinary tract infection; site not specified 185 7.0 660 6.3 1.47 (1.13-1.91) 
Calculus of urinary tract 45 1.7 129 1.2 1.35 (0.81-2.25) 
Calculus of kidney 25 0.9 91 0.9 1.24 (0.65-2.38) 
Calculus of ureter 18 0.7 60 0.6 1.36 (0.65-2.87) 
Other and unspecified urinary calculus 21 0.8 53 0.5 1.61 (0.73-3.53) 
Other diseases of kidney and ureters 107 4.0 327 3.1 1.56 (1.12-2.17) 
Hydronephrosis 25 0.9 51 0.5 2.40 (1.22-4.73) 
Other diseases of kidney and ureters 103 3.9 302 2.9 1.62 (1.15-2.29) 
Other diseases of bladder and urethra 45 1.7 122 1.2 1.69 (0.99-2.87) 
Other diseases of bladder and urethra 44 1.7 120 1.1 1.71 (1.00-2.92) 
Genitourinary symptoms and ill-defined conditions 112 4.2 596 5.7 1.18 (0.86-1.63) 
Hematuria 38 1.4 170 1.6 1.17 (0.69-1.98) 
Retention of urine 15 0.6 76 0.7 0.71 (0.30-1.66) 





Table 3.4:  Genital organ disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in comparison to a 
general population cohort of women. 
  1-5 Years 
  Survivors General Population  
Outcome n % n % HR 99% CI 
Diseases of female genital organs 976 36.9 2,756 26.2 1.71* (1.54-1.91) 
Nonmalignant breast conditions 240 9.1 682 6.5 1.70* (1.35-2.14) 
Inflammatory diseases of female pelvic organs 78 3.0 210 2.0 1.88 (1.27-2.80) 
Pelvic peritoneal adhesions 9 0.3 25 0.2 1.27 (0.41-4.00) 
Other inflammatory diseases of pelvic organs 88 3.3 166 1.6 2.16 (1.48-3.17) 
Endometriosis 15 0.6 47 0.5 2.05 (0.78-5.40) 
Menstrual disorders 14 0.5 175 1.7 0.80 (0.36-1.80) 
Ovarian cyst 12 0.5 92 0.9 0.58* (0.24-1.36) 
Menopausal disorders 108 4.1 604 5.8 1.30 (0.95-1.78) 
Other female genital disorders 107 4.0 487 4.6 1.97* (1.41-2.76) 
Female genital pain and other symptoms 107 4.0 326 3.1 1.51* (1.09-2.08) 






Table 3.4 Continued 
 5-10 Years 
 Survivors General Population   
Outcome n % n % HR 99% CI 
Diseases of female genital organs 531 20.1 1,895 18.0 1.33 (1.15-1.54) 
Nonmalignant breast conditions 146 5.5 445 4.2 1.47 (1.09-1.99) 
Inflammatory diseases of female pelvic organs 24 0.9 115 1.1 1.20 (0.63-2.28) 
Pelvic peritoneal adhesions 2 0.1 9 0.1 1.57 (0.12-20.09) 
Other inflammatory diseases of pelvic organs 27 1.0 95 0.9 1.59 (0.84-2.99) 
Endometriosis 2 0.1 14 0.1 0.84 (0.08-8.78) 
Menstrual disorders 5 0.2 111 1.1 0.40 (0.12-1.38) 
Ovarian cyst 1 0.0 46 0.4 0.09 (0.01-1.44) 
Menopausal disorders 44 1.7 364 3.5 0.80 (0.50-1.29) 
Other female genital disorders 25 0.9 245 2.3 1.07 (0.57-2.02) 
Female genital pain and other symptoms 36 1.4 212 2.0 1.06 (0.63-1.78) 
Other and unspecified female genital disorders 13 0.5 125 1.2 0.87 (0.37-2.04) 
Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race. The following outcomes were evaluated but no elevated risk 
was observed: cervicitis and endocervicitis, pelvic inflammatory disease, and prolapse of the female genital organs. 








Table 3.5: Risk factors for urinary and genital organ disorders among endometrial cancer 
survivors  
 Urinary System Disorders 
 1-5 Years 5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea     
Surgery only     
Surgery and radiation 1.46 (1.26-1.69) 1.24 (1.03-1.49) 
Surgery and chemotherapy 2.99 (2.21-4.04) 0.74 (0.31-1.80) 
Surgery, radiation, and chemotherapy 2.34 (1.81-3.02) 1.51 (0.98-2.32) 
Stageb     
Local     
Regional 1.45 (1.24-1.70) 1.3 (1.04-1.61) 
Advanced 3.43 (2.57-4.57) 1.49 (0.70-3.17) 
Grade b     
Grade I (Well differentiated)      
Grade II (Moderately differentiated)  1.20 (1.04-1.39) 1.07 (0.90-1.27) 
Grade III (Poorly differentiated) 1.57 (1.32-1.88) 0.86 (0.66-1.13) 
Grade IV (Undifferentiated) 2.78 (1.97-3.94) 0.89 (0.40-2.00) 
Year of Diagnosisc     
1997-2000     
2001-2004 1.35 (1.12-1.64) 1.15 (0.95-1.41) 
2005-2010 1.21 (1.02-1.44) 0.92 (0.75-1.12) 
2011-2012 1.19 (0.94-1.49) . . 
Age at Diagnosisd     
<50     
50-59 1.19 (0.96-1.47) 1.18 (0.91-1.52) 
60-69 1.39 (1.12-1.72) 1.55 (1.20-2.01) 
70-79 1.70 (1.35-2.14) 1.90 (1.44-2.52) 
80+ 2.20 (1.68-2.87) 2.67 (1.89-3.79) 
Charlson Comorbidity Indexe     
0     
1 1.40 (1.19-1.64) 1.83 (1.51-2.21) 
2+ 2.10 (1.80-2.46) 2.40 (1.95-2.95) 
Baseline BMIf     
<18 kg/m2 0.83 (0.34-2.01) 1.48 (0.61-3.63) 
18-24.9 kg/m2     
<25-29.9 kg/m2 1.07 (0.90-1.27) 1.16 (0.93-1.44) 





Table 3.5 Continued 
Models adjusted for a. Charlson Comorbidity Index, BMI, race, year of diagnosis, and age at 
diagnosis; b. age at diagnosis, diagnosis year, BMI, Charlson Comorbidity Index, Race; c. BMI, 
Charlson Comorbidity Index, race, endometrial cancer type; d. BMI, race, diagnosis year, 
Charlson Comorbidity Index; e.,age at diagnosis, diagnosis year, race; f. Charlson Comorbidity 
Index, age at diagnosis, race. 
 
  
 Genital Organ Disorders 
 1-5 Years 5-10 Years 
 HR 95% CI HR 95% CI 
Treatment Typea     
Surgery only     
Surgery and radiation 1.26 (1.08-1.47) 1.09 (0.88-1.35) 
Surgery and chemotherapy 1.62 (1.14-2.28) 1.81 (0.99-3.31) 
Surgery, radiation, and chemotherapy 1.52 (1.14-2.03) 1.02 (0.61-1.71) 
Stageb     
Local     
Regional 1.17 (0.98-1.39) 1.02 (0.79-1.32) 
Advanced 1.37 (0.92-2.02) 0.62 (0.23-1.68) 
Grade b     
Grade I (Well differentiated)      
Grade II (Moderately differentiated)  1.04 (0.90-1.20) 1.06 (0.87-1.28) 
Grade III (Poorly differentiated) 1.13 (0.93-1.37) 1.21 (0.92-1.59) 
Grade IV (Undifferentiated) 1.83 (1.22-2.75) 0.56 (0.18-1.76) 
Year of Diagnosisc     
1997-2000     
2001-2004 1.15 (0.96-1.38) 0.91 (0.73-1.13) 
2005-2010 0.97 (0.82-1.15) 0.82 (0.66-1.01) 
2011-2012 0.78 (0.61-1.00) . . 
Age at Diagnosisd     
<50     
50-59 1.09 (0.91-1.31) 0.93 (0.73-1.18) 
60-69 0.98 (0.81-1.18) 0.97 (0.76-1.24) 
70-79 0.77 (0.61-0.96) 0.64 (0.46-0.88) 
80+ 0.53 (0.37-0.74) 0.34 (0.18-0.63) 
Charlson Comorbidity Indexe     
0     
1 1.23 (1.05-1.45) 1.10 (0.88-1.37) 
2+ 1.18 (0.99-1.41) 1.14 (0.88-1.49) 
Baseline BMIf     
<18 kg/m2 1.05 (0.50-2.23) 1.30 (0.53-3.18) 
18-24.9 kg/m2     
<25-29.9 kg/m2 1.10 (0.92-1.30) 1.18 (0.94-1.49) 
















Endometrial cancer is the second most common cancer among female cancer survivors 
in the United States. There are an estimated 757,000 survivors in currently living in the United 
States. Endometrial cancer survivors experience a wide range of acute and long-term adverse 
gastrointestinal outcomes that vary by treatment type. Because of the increasing number of 
survivors in the United States as well as the high overall survival rate among those diagnosed 
with endometrial cancer, investigations of long-term adverse health outcomes in proximal 
bodily regions (such as the gastrointestinal system) that are likely to be affected by disease, 
treatment, and other comorbidities are important for the management and surveillance of 
these outcomes among endometrial cancer survivors. 
Cohorts of 2,648 endometrial cancer survivors diagnosed in the state of Utah between 1997 and 
2012, and 10,503 age-matched women from the general population were identified using the 
Utah Population Database. All ICD-9 diagnosis codes for gastrointestinal outcomes were 
collected from the state’s two largest healthcare systems, and statewide ambulatory surgery 
and inpatient visits. Multivariate Cox regression models were used to estimate hazard ratios 




Endometrial cancer survivors were at elevated risk for liver disease between 1-5 (HR: 
3.10, 99% CI: 2.52-3.87) and between >5-10 (HR: 1.58, 99% CI: 1.20-2.08) years after diagnosis, 
intestinal obstruction between 1-5 years (HR: 4.16, 99% CI: 2.87-6.04) and >5-10 (HR: 2.14, 99% 
CI: 1.30-3.52)  years after diagnosis, and biliary tract disorders between 1-5 (HR 2.02, 99% CI: 
1.58-2.59) and >5-10 (HR: 1.38, 99% CI: 1.00-1.91) years after diagnosis. Survivors were also 3 to 
5 times more likely to be diagnosed with an umbilical, ventral, or incisional hernia between 1-5 
years after diagnosis, with highly elevated risk persisting >5-10 years after diagnosis for ventral 
and incisional hernias. Among endometrial cancer survivors, individuals treated with surgery 
and chemotherapy were 6 times more likely to be diagnosed with liver disease than those 
treated with surgery alone. Elevated risk was also observed among survivors treated with 
radiation therapy therapy and/or chemotherapy compared to those treated with surgery alone 
for upper gastrointestinal disorders, lower gastrointestinal disorders, and abdominal hernias.  
Endometrial cancer survivors in this population were at higher risk for many 
gastrointestinal outcomes compared to women from the general population in the state of Utah 
between 1-5 and >5-10 years after diagnosis. This study presents strong evidence to suggest 
that increased monitoring for diseases of the gastrointestinal system is necessary for women 
diagnosed with endometrial cancer not only during the first several years after diagnosis, but 
after 5 years as well. 
 
4.2 Introduction 
Endometrial cancer is the second most common cancer among female cancer survivors 
in the United States; and both the rate of diagnosis and the number of survivors have been 
steadily increasing over the last several decades.1-4 Individuals diagnosed with endometrial 




outcomes, both acute and long-term. Risk for GI outcomes varies by treatment type; and 
investigations into specific gastrointestinal outcomes among individuals treated for endometrial 
cancer have produced mixed results, with some resolving within several months after treatment 
cessation and some persisting for years.5-10 Many of these studies have focused on symptoms 
that directly affect quality of life but lack validated measures for capturing outcomes, include a 
small number of individuals, lack control groups, include questions about symptoms that 
patients are reluctant to report, and suffer from loss to follow-up, making risk for long-term GI 
outcomes among endometrial cancer survivors difficult to quantify.5 
Much of the literature regarding GI complications due to radiation therapy  has focused 
on individuals treated for cervical cancer. Individuals treated for endometrial cancer have been 
observed to have fewer complications severe enough to require surgical intervention compared 
to those treated for cervical cancer, but are more likely to have long-term complications.6  
However, the proportion of endometrial cancer patients in this study diagnosed with higher 
grade, type II disease was larger than is typically expected among those diagnosed with 
endometrial cancer and the sample size was relatively small (n=75). In a retrospective study that 
examined treatment related complications among high-risk endometrial cancer patients 
(n=109), 66% of individuals who experienced any complications had either adverse GI or 
genitourinary outcomes.7 Among those who experienced GI complications, 14% were short-
term (<6 months) and 29% were long-term (>6 months). 
Increased risk for diarrhea, pain, nausea, bloating, bowel obstructions, rectal bleeding, 
fecal incontinence, and urgency due to RT-induced bowel damage has been observed among 
endometrial cancer patients years after diagnosis.8-10 It has been estimated that 90% of those 
treated with radiation therapy will experience a permanent change in their bowel habit and half 




included in this estimate is broad.11,12 Adverse GI outcomes among cancer survivors are often 
overlooked due to the priority of surveillance for disease recurrence, but GI symptoms remain 
among the most common complications of treatment and have the greatest impact on quality of 
life.13 Individuals with radiation therapy damage to the gastrointestinal tract are more likely to 
experience protein calorie malnutrition and micronutrient deficiencies similar to those found in 
individuals with inflammatory bowel disease.8,14 
In a study that compared gynecologic cancer survivors (n=356) in Sweden treated with 
radiation therapy compared to general population controls, risks for urgency and emptying 
stools into clothing without warning were elevated among survivors.15 Treatment with external 
beam radiation therapy has been associated with adverse GI outcomes among endometrial 
cancer survivors.16,17 However, GI outcomes have typically been measured in broad categories in 
populations <1,000 endometrial cancer survivors with broad variation in the length of time since 
diagnosis. Individuals treated with external beam radiation therapy have been observed to have 
more GI complications within 5 years after diagnosis than those treated with brachytherapy, 
including diarrhea, leakage, and the need to stay within close proximity to a toilet, all of which 
limit daily activities.18 In a study that compared rectal bleeding among individuals treated with 
external beam radiation therapy (n=166) and/or brachytherapy (n=182), the cumulative 
incidence of rectal bleeding increased significantly among individuals treated with external 
beam radiation therapy and external beam radiation therapy and brachytherapy compared to 
those treated with brachytherapy alone from the time of treatment cessation to 5 years.19 
Nearly 18% of those treated with external beam radiation therapy and brachytherapy 
experienced rectal bleeding, though the addition of brachytherapy to external beam radiation 
therapy did not significantly increase risk for rectal bleeding. In a study that compared 




therapy and surgery (n=190) and surgery alone (n=202), significant differences in both the 
frequency and severity of GI toxicities have been observed between those treated with external 
beam radiation therapy and surgery compared to those treated with surgery alone, though no 
increased risk of bowel obstruction was observed.20 This study did not differentiate between 
acute and long-term complications. 
In addition to complications due to treatment with radiation therapy, survivors may also 
experience surgical complications. Risk for incisional hernia among those diagnosed with 
endometrial cancer varies by surgical procedure. Studies that focus on the immediate 
complications due to surgery may miss increased long-term risk for incisional hernias. These are 
common even among women treated with single-port laparoscopy, which generally has fewer 
complications than laparotomy, including other types of abdominal hernias and bowel 
injuries.21,22 
Long-term surveillance of surgically treated patients has suggested that regional 
complications due to surgery are usually resolved within 1 year. Studies that have investigated 
the long-term effects of treatment with radiation therapy on the GI system have been mixed, 
with some resolving within a few years7 and some providing evidence that treatment with 
radiation therapy can cause permanent damage to tissue architecture of the GI systems that can 
persist for years after treatment cessation.11.12 Large cohort studies that are sufficiently 
powered to examine a large number of GI outcomes from reliable sources, such as electronic 
medical records, that have a detrimental effect on quality of life and mortality are necessary to 








4.3.1 Data Collection 
An initial cohort of 3,624 endometrial cancer survivors was identified using the Utah 
Population Database.  Diagnosis data were available from the statewide SEER Utah Cancer 
Registry for women aged 18 and over, diagnosed with invasive first primary endometrial cancer 
between 1997 and 2012 in the state of Utah (SEER ICD-O-3 codes: C54.0-C55.9). Endometrial 
cancer histological subtypes adenocarcinoma, endometrioid, mucinous adenocarcinoma, and 
adenocarcinoma with squamous differentiation were classified as type I (ICD-O-3 morphology 
codes: 8140, 8260, 8380, 8382, 8480, 8482, 8560, and 8570) and clear-cell carcinomas and 
papillary serous carcinomas as type II (ICD-O-3 morphology codes: 8310, 8441, and 8460).23 
Eligible survivors were required to have stage and grade included in diagnosis records from the 
Utah Cancer Registry and to have lived in the state of Utah for at least 1 year after diagnosis. 
Survivors were matched with up to 5 women from the general population on birth year and 
birth state. 
Outcome data used for this study included statewide ambulatory and inpatient data 
from the Utah Department of Health and Electronic Data Warehouse data from Intermountain 
Health Care and the University of Utah Health Sciences Center. The Utah Population Database 
data included records from the Utah Cancer Registry, Utah Driver’s License, vital records, and 
the Utah Department of Health. Statewide ambulatory and inpatient records as well as those 
from the University of Utah and Intermountain Healthcare systems were linked via the Utah 
Population Database.  
Electronic medical record data were available prior to 1992, but all three major sources 
did not have comprehensive electronic medical record data for individuals in these cohorts until 




this analysis to allow adequate time prior to cancer diagnosis to capture prior diagnoses of the 
GI outcomes of interest. A total of 153 endometrial cancer patients were excluded because their 
cancer was not staged, 470 because grade was missing, 285 because follow-up time did not 
exceed 1 year, 65 because their Utah residence did not exceed 1 year. The stage and grade were 
important for our study because we were interested in investigating Type I and II endometrial 
cancer subtypes, which are grouped with these variables. There were a total of 2,648 
endometrial cancer survivors and 10,503 individuals from the general population included in the 
final sample.   
 
4.3.2 Categorization of Outcomes 
Outcome data from the statewide, University of Utah Health Sciences Center, and 
Intermountain Healthcare systems included all available ICD-9 diagnosis codes, as well as 
diagnosis date which allowed for time to outcome to be calculated. The Clinical Classification 
Software developed by the Health Cost and Utilization Project was used to categorize ICD-9 
codes into 4 levels of specificity (Levels 1-4).24 Diseases of the GI system (level 1) according to 
the Clinical Classification Software were used in this analysis. Level 2 outcomes included upper 
GI disorders, lower GI disorders, biliary tract disease, liver disease, pancreatic disorders, 
intestinal infection, disorders of the teeth and jaw, diseases of the mouth (excluding dental), 
abdominal hernia, GI hemorrhage, noninfectious gastroenteritis, and other GI disorders. More 
specific outcomes within these categories were analyzed as level 3 and 4 outcomes. Examples of 
this hierarchy include upper GI disorders (level two), esophageal disorders (level 3), esophagitis 
(level 4).  
Long-term GI outcomes were measured at 1-5 years and >5-10 years after endometrial 




from the endometrial cancer survivor’s initial cancer diagnosis to the date of diagnosis for each 
outcome, last date of follow-up, or date of death. Individuals who did not have that outcome 
were censored at the date of last follow-up (last residence date in Utah or death) if that date fell 
within the analysis time period (1-5 years or >5-10 years) or at the end of each analysis time 
period if their date of last follow-up exceeded the end of the analysis time period. Levels 3 or 4 
outcomes diagnosed prior to the start of each analysis time period were considered prevalent 
cases of those outcomes and were excluded from the models.  Level 1 and 2 outcomes were 
broader, thus we did not exclude prevalent diagnoses.    
 
4.3.3 Statistical Analysis 
Chi-square tests were used to compare baseline characteristics between the cancer and 
general population cohorts. Univariate and multivariate Cox proportional hazard models were 
used to calculate hazard ratios for long-term GI outcomes at 1-5 years and >5-10 years after 
endometrial cancer diagnosis. We used 99% confidence intervals to account for the penalty 
imposed by multiple testing due to the large number of outcomes examined in this analysis. 
Multivariate models were adjusted for matching factors, baseline body mass index (BMI), 
baseline Charlson Comorbidity Index,25 and race. Cox proportional hazard models were also 
used to investigate risk factors such as treatment type, stage, grade, age at diagnosis, year of 
diagnosis, race, BMI, and rural/urban residence for upper GI disorders, lower GI disorders, 
abdominal hernias, and liver disease among endometrial cancer survivors. The proportional 
hazards assumption was checked for each model using a test for nonzero slope of the 
Schoenfeld residuals vs time. Models that were in violation of the proportional hazards 
assumption were then tested with flexible parametric survival models with restricted cubic 




were no substantive differences. 
Baseline BMI values at least 1 year prior to cancer survivors’ endometrial cancer 
diagnosis were calculated from the driver’s license records.  For the cancer-free women, the 
most recent BMI value recorded at least 1 year prior to the endometrial cancer diagnosis date of 
the matched cancer patient was included. Approximately 35% of the survivors cohort and 39% 
of the general population cohort were missing baseline BMI. For individuals missing BMI, BMI 
values were imputed using a linear regression model with 10 imputations that included cancer 
diagnosis, baseline Charlson Comorbidity Index, and age at endometrial cancer diagnosis as 
covariates. Models were run with and without the imputed values to assure that the inferences 
did not change due to the imputation of BMI.  
 
4.4 Results 
The endometrial cancer survivors cohort had a higher proportion of obese individuals 
(44.2% vs 19.2%) than the general population cohort (p<0.001, Table 4.1). Nearly 81.5% of the 
endometrial cancer survivors were diagnosed with grade I or II and 80.3% with stage I disease 
(Table 4.2). Among endometrial cancer survivors, 68.5% were treated with surgery alone, 21.9% 
with surgery and radiation therapy, 3.2% with surgery and chemotherapy, and 4.7% with 
surgery, radiation therapy, and chemotherapy.   
Endometrial cancer survivors were more likely to be diagnosed with biliary tract, liver, 
and pancreatic diseases at both 1-5 years and >5-10 years after diagnosis (Table 4.3). Elevated 
risk for cholelithiasis without cholecystitis was observed at 1-5 years (HR: 1.73, 99% CI: 1.16-
2.58) and at >5-10 years (HR: 1.95, 99% CI: 1.21-3.13) after diagnosis. Survivors were 3 times 
more likely to be diagnosed with liver disease between 1 and 5 years after diagnosis, with 




be diagnosed with acute pancreatitis >5-10 but not between 1-5 years after diagnosis. 
Endometrial cancer survivors were 83% more likely to be diagnosed with a lower GI 
disorder between 1-5 years and 33% more likely between >5-10 years after diagnosis compared 
to individuals from the general population (Table 4.4). The highest risk was observed for 
intestinal hernias, with endometrial cancer survivors being 4 times more likely to be diagnosed 
with an intestinal hernia between 1-5 and twice as likely between >5-10 years after diagnosis. 
Within this category, survivors were 7 times more likely to be diagnosed with peritoneal or 
intestinal adhesions between 1-5 years and 3 times more likely between >5-10 years after 
diagnosis and were three times more likely to be diagnosed with paralytic ileus between 1-5 
years after diagnosis, but no elevated risk was observed between>5-10 years after diagnosis. 
Risk for anal and rectal conditions among endometrial cancer survivors was twice that of general 
population individuals, but elevated risk did not persist >5-10 years after diagnosis.  
Endometrial cancer survivors were at elevated risk for abdominal hernias between 1-5 
(HR: 2.18, 99% CI: 1.80-2.65) and >5-10 (HR: 1.44, 99% CI: 1.11-1.87) years after diagnosis (Table 
4.5). Survivors were 3 to 5 times more likely to be diagnosed with umbilical, ventral, and 
incisional hernias without the presence of gangrene between 1-5 years. Elevated risk persisted 
between >5-10 years after diagnosis for ventral and incisional hernias. Elevated risk for 
gastrointestinal hemorrhage was observed among survivors between 1-5 years (HR: 1.90, 99% 
CI: 1.48-2.43) and >5-10 years (HR: 1.43, 99% CI: 1.03-1.99). No elevated risk among endometrial 
cancer survivors for intestinal infection was observed between 1-5 years after diagnosis; but 
between >5-10 years, endometrial cancer survivors were more than twice as likely be diagnosed 
with an intestinal infection. Survivors were at elevated risk for constipation between 1-5 and >5-





Among endometrial cancer survivors, increased risk for upper GI disorders, lower GI 
disorders, abdominal hernias, and liver disease was observed for advanced stage and high grade 
endometrial cancer diagnoses at 1-5 years but not between >5-10 years after diagnosis (Table 
4.6). Elevated risk for abdominal hernias and lower GI disorders was observed among individuals 
treated with chemotherapy and/or radiation therapy compared to those treated with surgery 
alone between 1-5 years and >5-10 years after diagnosis. Individuals treated with surgery and 
chemotherapy were 6 times more likely to be diagnosed with liver disease compared to those 
treated with surgery alone (HR: 6.12, 99% CI: 4.19-8.95) between 1-5 years. No association 
between obesity and upper GI disorders, lower GI disorders, abdominal hernias, and liver 
disease compared to normal weight individuals was observed. Survivors who were overweight 
were at increased risk for upper GI disorders between 1-5 and >5-10 years after diagnosis and 
for abdominal hernias between >5-10 years after diagnosis compared to normal weight 
individuals. 
Figure 4.1 shows the cumulative incidences of select GI outcomes between 1 and 10 
years after diagnosis between endometrial cancer survivors and individuals from the general 
population cohort.  
 
4.5 Discussion 
This is the first large cohort study to compare all available GI outcomes from electronic 
medical record data between endometrial cancer survivors and matched individuals from the 
general population. This analysis supports many of the findings of prior investigations by 
showing an association between endometrial cancer diagnosis and several well-documented 
conditions related to treatment type. In this population, endometrial cancer survivors were at 




biliary tract disease, liver disease, pancreatic disorders, abdominal hernia, GI hemorrhage, and 
other GI disorders) between 1-5 and >5-10 years after diagnosis. These results also provide 
evidence that those treated with radiation therapy and/or chemotherapy compared to those 
treated with surgery alone are at higher risk for both upper and lower GI disorders and liver 
disease within 5 years of diagnosis, with treatment with chemotherapy associated with a six-fold 
increase in risk for liver disease.  
These results present a number of important additions to the body of literature 
concerning long-term, adverse GI outcomes among endometrial cancer survivors. The majority 
of investigations into these associations have focused on symptoms that affect health-related 
quality of life among survivors that were measured using self-report from patients on subjects 
that are personal and may be less likely to be reported or lack validated measures (such as 
diagnosis from a clinician) to record outcomes. Studies that measure complications related to 
treatment are largely focused on acute conditions or those that may indicate disease recurrence 
at the expense of long-term conditions that can affect quality of life.  
Biliary tract disorders such as gallstones have been loosely implicated as potential risk 
factors for endometrial cancer, though this is likely due to the role of obesity as a shared risk 
factor.26,27 We observed that risk for gallstones without gallbladder inflammation and 
gallbladder inflammation without gallstones were higher among cancer survivors in both time 
periods, while risk for gallstones with gallbladder inflammation was not elevated among cancer 
survivors. Our models were adjusted for baseline BMI, but misclassification is possible due to 
the imputation of BMI values in approximately 38% of the total population. This is the first study 
to observe elevated risk for a new diagnosis of gallstones and gallbladder inflammation among 
endometrial cancer survivors years after diagnosis. Pancreatic disorders are also related to BMI, 




was observed. Our results suggest that risk for both pancreatic conditions overall and for acute 
pancreatitis is higher after 5 years than between 1-5 years. Pancreatitis due to chemotherapy is 
rare (1.4-2%).28-30 Similarly, evidence for RT-induced pancreatitis is scarce and comes primarily 
from case reports.31-33 
In our results, individuals treated with chemotherapy were 6 times more likely to be 
diagnosed with liver disease compared to those treated with surgery alone between 1-5 years 
after diagnosis. Risk for liver disease was also highly elevated among survivors compared to 
individuals in the general population, but calculation of this risk included subcategories for 
which large effect sizes were observed such as ascites and other and unspecified liver disorders, 
which may contain multiple conditions with potentially differing etiologies. Regardless, the 
observation that risk for liver disease overall is higher among those treated with chemotherapy 
supports prior evidence of toxicity in the liver34-36 due to treatment with chemotherapy 
observed among survivors of other cancers. This is the first study to quantify the risk of liver 
disease overall in endometrial cancer survivors compared to controls from the general 
population.  
Endometrial cancer survivors were at increased risk for lower GI disorders overall during 
both time periods. The HRs were markedly higher for intestinal obstructions, peritoneal 
adhesions, and peritonitis and intestinal abscess between 1-5 and >5-10 years after diagnosis, 
while conditions such as paralytic ileus, anal and rectal conditions, and diverticulosis were much 
more likely among endometrial cancer survivors between 1-5 years but not >5-10 years after 
diagnosis. Some prior studies have suggested that RT-induced bowel damage can be 
permanent.11,12 These results did not measure outcomes >10 years after diagnosis, but our 
results suggest that several GI outcomes are more common among endometrial cancer survivors 




among survivors between 1-5 years but not significantly elevated between >5-10 years. Prior 
studies that have examined lower GI disorders among endometrial cancer survivors have 
primarily relied on patient reported outcomes that may be secondary to other GI conditions, 
which makes comparisons of risk for the specific outcomes measured in this study difficult. 
Several studies that have examined risk for anal and rectal conditions and bowel injury found 
that endometrial cancer survivors are at elevated risk for these conditions,8,15 but in our 
population risk was higher than what has been previously observed. 
Abdominal hernias, especially incisional hernias are well documented surgical 
complications, but these are often diagnosed post-operatively. The current study’s results 
suggest that newly diagnosed incisional hernias are more likely to be diagnosed in endometrial 
cancer survivors even between >5-10 years after diagnosis. Few studies have examined long-
term risk for ventral hernias among endometrial cancer survivors, but our results suggest that 
survivors are more than 5 times more likely to be diagnosed between 1-5 years and 4 times 
more likely to be diagnosed between >5-10 years. These outcomes are generally thought to be 
the result of surgical treatment, but our results show elevated risk among survivors treated with 
surgery and/or chemotherapy compared to those treated with surgery alone during both time 
periods. This may be explained by the use of chemotherapy and/or radiation therapy in more 
advanced cases of disease that would also require more aggressive surgeries which could result 
in more frequent complications, or are due to the use of chemotherapeutic agents that are 
associated with compromised wound healing.37  
This study has a number of significant strengths. The large sample size (>2,600 
endometrial cancer survivors and >10,500 cancer free women) and use of electronic medical 
record data provide a more objective measure of the experience of endometrial cancer 




this study came from the state’s two largest healthcare systems as well as statewide ambulatory 
surgery and inpatient data, providing a more complete record of the medical history of study 
patients. These data also contain a large amount of follow-up time for individuals in both 
cohorts. The mean follow-up time among survivors is 8.5 years. Approximately 27% have total 
follow-up time between 1 and 5 years, 39% between 5 and 10 years, and 34% in excess of 10 
years. In contrast to cancer survivor studies that rely on self-reports of disease which are 
susceptible to survival bias, our study is less susceptible to survival bias because we used long-
term health records as the source of disease diagnoses. 
This study also has a number of limitations. While the data used for this study are 
comprised of comprehensive electronic medical record data from the two largest healthcare 
systems in the state, as well as statewide ambulatory surgery and inpatient data, there remains 
the possibility that study participants will have been diagnosed with outcomes of interest to 
these analyses in hospitals and clinics not covered by the data sources. However, approximately 
99.6% of cancer patients and 98.6% of the general population cohort did have records in these 
data sources. Additionally, because 42.7% of individuals in the survivor cohort were diagnosed 
after 2006, the potential to examine risk for these outcomes after 10 years is limited due to lack 
of follow-up time for this proportion of the study population. However, with the Utah 
Population Database as a data source, we are able to update our analysis on a regular basis for 
further analysis.  While data were available to investigate treatment related risk factors among 
endometrial cancer survivors, these data were limited to broad treatment categories and did 
not include potentially informative factors such as radiation therapy type and dosage, specific 
chemotherapy agents, and duration of treatment. However, the treatment data that were 
available did provide evidence that risk for several GI outcomes vary by treatment type. It is also 




increased monitoring during routine follow-up in the years following diagnosis. 
Future research is necessary to more accurately assess causal relationships between 
treatment for endometrial cancer and the outcomes measured in this study. While the 
mechanisms of damage to the GI system due to surgery, chemotherapy and radiation therapy 
have been investigated more completely for cervical cancer, more studies that examine these 
associations among endometrial cancer survivors are necessary. Further analysis that 
incorporates more specific treatment-related factors are also needed. Additionally, because 
electronic medical record data are derived from sources that are constantly updated, this study 
has the potential to examine these outcomes in an increasing number of survivors and over a 
longer period of time as new data are collected. 
In conclusion, endometrial cancer survivors in this cohort were at higher risk for a 
number of long-term GI outcomes. Many of the conditions examined in this study have shared 
risk factors with endometrial cancer, but the ability to control for many of these risk factors 
provides a clearer picture than has been previously available. It is evident from these results 
that the survivors of endometrial cancers in this cohort experienced a high burden of adverse GI 
outcomes, especially lower GI disorders, abdominal hernias, gastrointestinal hemorrhage, and 
liver disease. These results suggest that increased monitoring for GI disorders over long periods 
of time among endometrial cancer survivors may be warranted. Further, these results highlight 
the need to place more emphasis on survivorship in addition to acute complications of 
treatment that encompass the majority of the literature on treatment-related effects. 
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population   
  n=2,648 n=10,503   
  n  % n % p 
Birth Year           
<1920 116 4.38 473 4.50   
1920-1929 310 11.71 1,192 11.35   
1930-1939 541 20.43 2,015 19.18   
1940-1949 787 29.72 3,085 29.37   
1950-1959 591 22.32 2,444 23.27   
>1960 303 11.44 1,294 12.32 0.54 
Race           
White 2,525 95.35 9,617 91.56   
Black 10 0.38 29 0.28   
American 
Indian/Alaskan Native 111 1.06 32 1.21   
Asian 277 2.64 19 0.72   
Pacific Islander 60 0.57 48 1.81   
Unknown 14 0.53 409 3.89 <0.001 
Vital Status           
        Alive 1,924 72.66 8,906 84.79   
        Dead 724 27.34 1,597 15.21 <0.001 
Baseline BMI           
        <18 kg/m2 18 0.68 307 2.92   
        18-24.9 kg/m2 645 24.36 4,994 47.55   
        25-29.0 kg/m2 814 30.74 3,190 30.74   
        >30 kg/m2 1,171 44.22 2,012 19.16 <0.001 
Age Attained at the End of 
Follow-up           
        <50 161 6.08 697 6.64   
        50-59 389 14.69 1,697 16.16   
        60-69 826 31.19 3,142 29.92   
        70-79 692 26.13 2,637 25.11   
        80-89 442 16.69 1,787 17.01   
        90+ 138 5.21 543 5.17 0.303 
Follow up Period           
        1-5 years 726 27.42 2,742 26.11   
        >5-10 years 1,028 38.82 4,062 38.67   
        >10-15 years 595 22.47 2,576 24.53   






Table 4.2: Clinical characteristics among endometrial cancer survivors 
 
Endometrial Cancer (n=2,648) 
Diagnosis Year n % 
        1997-2000 563 21.26 
        2001-2003 471 17.79 
        2004-2006 483 18.24 
        2007-2009 572 21.60 
        2010-2012 559 21.11 
Age at Diagnosis     
        <40 140 5.29 
        40-49 307 11.59 
        50-59 786 29.68 
        60-69 758 28.63 
        70-79 451 17.03 
        80+ 206 7.78 
Grade     
        Grade I (Well differentiated)  1,314 49.62 
        Grade II (Moderately differentiated)  845 31.91 
        Grade III (Poorly differentiated) 421 15.90 
        Grade IV (Undifferentiated) 68 2.57 
Stage     
        Local 10,565 80.34 
        Regional 2,154 16.38 
        Advanced 432 3.28 
Histology     
        Endometrioid adenocarcinoma 1,853 69.98 
        Adenocarcinoma with squamous differentiation 56 2.11 
        Serous adenocarcinoma 87 3.29 
        Clear cell adenocarcinoma 17 0.64 
        Mixed cell adenocarcinoma 47 1.77 
        Mucinous adenocarcinoma 45 1.70 
        Carcinosarcoma 26 0.98 
        Stromal sarcoma 44 1.66 
        Leiomyosarcoma 41 1.55 
        Other 432 16.31 
Endometrial Cancer Type     
        Type I 2,300 86.86 
        Type II 87 3.29 
        Unknown 261 9.86 
Treatment Type   
        Surgery only 1,813 68.47 
        Surgery and radiation 579 21.87 
        Surgery and chemotherapy 84 3.17 
        Surgery, radiation, and chemotherapy 124 4.68 





Table 4.3:  Biliary, liver, and pancreatic disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in 
comparison to a general population cohort of women. 
  1-5 Years 
  Survivors General Population   
outcome n % n % HR 99% CI 
Biliary tract disease 206 7.8 385 3.7 2.02 (1.58-2.59) 
Cholelithiasis with acute cholecystitis 15 0.6 46 0.4 1.20 (0.51-2.85) 
Cholelithiasis with other cholecystitis 51 1.9 156 1.5 1.08 (0.68-1.71) 
Cholelithiasis without mention of cholecystitis 81 3.1 150 1.4 1.73 (1.16-2.58) 
Calculus of bile duct 15 0.6 33 0.3 1.34 (0.53-3.38) 
Cholecystitis without cholelithiasis 41 1.6 73 0.7 2.28 (1.32-3.94) 
Other biliary tract disease 57 2.2 114 1.1 2.05 (1.29-3.26) 
Liver disease 353 13.3 470 4.5 3.10* (2.52-3.82) 
Other liver diseases 234 8.8 365 3.5 2.75* (2.13-3.54) 
Cirrhosis of liver without mention of alcohol 6 0.2 27 0.3 0.90 (0.25-3.23) 
Liver abscess and sequelae of chronic liver disease 11 0.4 23 0.2 2.61 (0.78-8.67) 
Ascites 62 2.3 42 0.4 6.98* (3.73-13.07) 
Other and unspecified liver disorders 217 8.2 340 3.2 2.65* (2.04-3.45) 
Pancreatic disorders (not diabetes) 45 1.7 101 1.0 1.84 (1.11-3.06) 
Acute pancreatitis 24 0.9 67 0.6 1.54 (0.79-3.01) 
Chronic pancreatitis 2 0.1 7 0.1 0.58 (0.04-7.91) 







Table 4.3 Continued 
 5-10 Years 
 Survivors General Population   
 n % n % HR 99% CI 
Biliary tract disease 115 4.3 321 3.1 1.38 (1.00-1.91) 
Cholelithiasis with acute cholecystitis 17 0.6 33 0.3 2.12 (0.86-5.21) 
Cholelithiasis with other cholecystitis 35 1.3 114 1.1 1.25 (0.71-2.21) 
Cholelithiasis without mention of cholecystitis 61 2.3 118 1.1 1.95 (1.21-3.13) 
Calculus of bile duct 12 0.5 27 0.3 1.86 (0.61-5.60) 
Cholecystitis without cholelithiasis 21 0.8 66 0.6 1.21 (0.56-2.59) 
Other biliary tract disease 35 1.3 90 0.9 1.58 (0.85-2.94) 
Liver disease 164 6.2 428 4.1 1.58 (1.20-2.08) 
Other liver diseases 111 4.2 328 3.1 1.56 (1.12-2.19) 
Cirrhosis of liver without mention of alcohol 4 0.2 23 0.2 0.53 (0.09-3.06) 
Liver abscess and sequelae of chronic liver disease 6 0.2 21 0.2 1.49 (0.37-6.01) 
Ascites 16 0.6 21 0.2 2.84 (0.95-8.49) 
Other and unspecified liver disorders 103 3.9 315 3.0 1.49 (1.06-2.10) 
Pancreatic disorders (not diabetes) 36 1.4 75 0.7 2.18 (1.21-3.92) 
Acute pancreatitis 20 0.8 37 0.4 2.32 (1.04-5.17) 
Chronic pancreatitis 1 0.0 6 0.1 1.52 (0.05-44.86) 
Other pancreatic disorders 15 0.6 27 0.3 2.18 (0.84-5.65) 
Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race 







Table 4.4:  Lower gastrointestinal disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in 
comparison to a general population cohort of women. 
   1-5 Years 
  Survivors General Population  
outcome n % n % HR 99% CI 
Lower gastrointestinal disorders 567 21.4 1,329 12.7 1.82* (1.58-2.10) 
Appendicitis and other appendiceal conditions 19 0.7 39 0.4 1.96 (0.88-4.40) 
Acute appendicitis with abscess or peritonitis 7 0.3 8 0.1 3.74* (0.83-16.88) 
Acute appendicitis without abscess or peritonitis 4 0.2 27 0.3 0.60 (0.14-2.63) 
Acute appendicitis; not otherwise specified 2 0.1 4 0.0 2.43 (0.20-29.32) 
Other appendiceal conditions 8 0.3 8 0.1 5.87 (0.93-36.91) 
Regional enteritis and ulcerative colitis 14 0.5 36 0.3 1.55 (0.65-3.67) 
Intestinal obstruction without hernia 120 4.5 128 1.2 4.16* (2.87-6.04) 
Paralytic ileus 55 2.1 66 0.6 3.28 (1.97-5.48) 
Impaction of intestine 3 0.1 7 0.1 1.78 (0.22-14.43) 
Peritoneal or intestinal adhesions 35 1.3 21 0.2 7.15 (3.12-16.40) 
Other intestinal obstruction 96 3.6 67 0.6 6.64* (4.08-10.82) 
Diverticulosis and diverticulitis 249 9.4 728 6.9 1.51* (1.22-1.87) 
Diverticulosis 248 9.4 715 6.8 1.53* (1.24-1.90) 
Diverticulitis 31 1.2 99 0.9 1.21 (0.68-2.13) 
Anal and rectal conditions 80 3.0 157 1.5 2.09 (1.40-3.10) 






Table 4.4 Continued 
Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race 
*Models in violation of the proportional hazards assumption that were evaluated using flexible parametric survival models with restricted cubic 
splines 
  
 5-10 Years 
 Survivors General Population   
 n % n % HR 99% CI 
Lower gastrointestinal disorders 332 12.5 1,117 10.6 1.33 (1.11-1.60) 
Appendicitis and other appendiceal conditions 7 0.3 27 0.3 1.52 (0.44-5.20) 
Acute appendicitis with abscess or peritonitis 2 0.1 5 0.1 1.35 (0.13-13.67) 
Acute appendicitis without abscess or peritonitis 5 0.2 16 0.2 2.54 (0.47-13.65) 
Acute appendicitis; not otherwise specified 3 0.1 4 0.0 2.39 (0.19-30.71) 
Other appendiceal conditions 3 0.1 6 0.1 2.97 (0.29-30.31) 
Regional enteritis and ulcerative colitis 8 0.3 31 0.3 1.28 (0.43-3.82) 
Intestinal obstruction without hernia 51 1.9 109 1.0 2.14 (1.30-3.52) 
Paralytic ileus 26 1.0 60 0.6 1.97 (1.00-3.89) 
Impaction of intestine 2 0.1 11 0.1 1.01 (0.12-8.42) 
Peritoneal or intestinal adhesions 14 0.5 20 0.2 3.13 (1.17-8.41) 
Other intestinal obstruction 39 1.5 58 0.6 3.01 (1.61-5.63) 
Diverticulosis and diverticulitis 115 4.3 549 5.2 1.04 (0.77-1.42) 
Diverticulosis 113 4.3 529 5.0 1.07 (0.79-1.46) 
Diverticulitis 19 0.7 93 0.9 0.93 (0.45-1.96) 
Anal and rectal conditions 29 1.1 126 1.2 1.12 (0.63-1.99) 





Table 4.5:  Other gastrointestinal disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in comparison 
to a general population cohort of women. 
  1-5 Years 
  Survivors General Population  
outcome n % n % HR 99% CI 
Intestinal infection 45 1.7 97 0.9 1.67 (0.97-2.85) 
Disorders of teeth and jaw 39 1.5 121 1.2 1.14 (0.67-1.94) 
Diseases of mouth; excluding dental 50 1.9 146 1.4 1.36* (0.86-2.15) 
Abdominal hernia 353 13.3 644 6.1 2.18* (1.80-2.65) 
Inguinal hernia 15 0.6 45 0.4 1.39 (0.60-3.21) 
Diaphragmatic hernia 140 5.3 334 3.2 1.67* (1.25-2.24) 
Other abdominal hernia 141 5.3 132 1.3 4.01 (2.82-5.70) 
Umbilical hernia without obstruction/gangrene 36 1.4 48 0.5 3.21 (1.71-6.02) 
Ventral hernia without obstruction/gangrene 67 2.5 39 0.4 5.42 (2.96-9.95) 
Incisional hernia with obstruction/gangrene 23 0.9 15 0.1 4.32 (1.62-11.51) 
Incisional hernia without obstruction/gangrene 71 2.7 48 0.5 5.18* (3.04-8.83) 
Other and unspecified hernia 22 0.8 22 0.2 5.15 (1.90-13.96) 
Gastrointestinal hemorrhage 196 7.4 462 4.4 1.90 (1.48-2.43) 
Hemorrhage from gastrointestinal ulcer 18 0.7 46 0.4 2.37* (1.01-5.54) 
Melena 76 2.9 156 1.5 2.10* (1.40-3.16) 
Hemorrhage of rectum and anus 77 2.9 174 1.7 2.00 (1.35-2.96) 
Hemorrhage of gastrointestinal tract 45 1.7 111 1.1 1.74 (1.02-2.96) 
Noninfectious gastroenteritis 101 3.8 272 2.6 1.44 (1.03-2.01) 
Other gastrointestinal disorders 779 29.4 1,816 17.3 1.86* (1.64-2.11) 
Constipation 184 7.0 365 3.5 2.12 (1.63-2.77) 
























Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race. syndrome, other esophageal bleeding, hematemesis, and 
dysphagia. 
*Models in violation of the proportional hazards assumption that were run using flexible parametric survival models with restricted cubic splines  
 5-10 Years 
 Survivors General Population   
 n % n % HR 99% CI 
Intestinal infection 38 1.4 87 0.8 2.21 (1.25-3.93) 
Disorders of teeth and jaw 31 1.2 94 0.9 1.78 (0.96-3.33) 
Diseases of mouth; excluding dental 50 1.9 123 1.2 1.77 (1.06-2.94) 
Abdominal hernia 167 6.3 500 4.8 1.44 (1.11-1.87) 
Inguinal hernia 4 0.2 31 0.3 0.63 (0.14-2.80) 
Diaphragmatic hernia 63 2.4 249 2.4 1.21 (0.80-1.82) 
Other abdominal hernia 44 1.7 102 1.0 1.77 (1.04-3.02) 
Umbilical hernia without obstruction/gangrene 18 0.7 43 0.4 1.68 (0.73-3.88) 
Ventral hernia without obstruction/gangrene 26 1.0 23 0.2 4.24 (1.80-9.99) 
Incisional hernia with obstruction/gangrene 8 0.3 9 0.1 2.38 (0.55-10.28) 
Incisional hernia without obstruction/gangrene 20 0.8 22 0.2 3.34 (1.32-8.41) 
Other and unspecified hernia 10 0.4 17 0.2 1.50 (0.40-5.67) 
Gastrointestinal hemorrhage 98 3.7 328 3.1 1.43 (1.03-1.99) 
Hemorrhage from gastrointestinal ulcer 13 0.5 37 0.4 1.33 (0.52-3.44) 
Melena 36 1.4 106 1.0 1.83 (1.03-3.24) 
Hemorrhage of rectum and anus 24 0.9 115 1.1 1.08 (0.58-2.01) 
Hemorrhage of gastrointestinal tract 33 1.3 97 0.9 1.78 (0.99-3.20) 
Noninfectious gastroenteritis 73 2.8 222 2.1 1.45 (0.98-2.16) 
Other gastrointestinal disorders 449 17.0 1,489 14.2 1.43* (1.22-1.68) 
Constipation 93 3.5 304 2.9 1.44 (1.01-2.07) 




Table 4.6: Risk factors for upper and lower gastrointestinal disorders among endometrial 
cancer survivors  
  Upper Gastrointestinal Disorders 
  1-5 Years 5-10 Years 
 HR 99% CI HR 99% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.27 (1.05-1.54) 1.22 (0.97-1.54) 
Surgery and chemotherapy 1.65 (1.04-2.62) 1.18 (0.48-2.86) 
Surgery, radiation, and chemotherapy 2.17 (1.56-3.03) 1.76 (1.08-2.89) 
Stageb     
Local Reference 
Regional 1.43 (1.17-1.76) 1.02 (0.76-1.35) 
Advanced 1.92 (1.23-2.99) 1.00 (0.37-2.72) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.28 (1.06-1.53) 1.16 (0.94-1.43) 
Grade III (Poorly differentiated) 1.48 (1.18-1.87) 1.10 (0.81-1.51) 
Grade IV (Undifferentiated) 1.62 (0.95-2.77) . . 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.14 (0.90-1.45) 1.16 (0.91-1.47) 
2005-2010 1.09 (0.88-1.35) 0.80 (0.62-1.03) 
2011-2012 0.75 (0.54-1.03) . . 
Age at Diagnosisd     
<50 Reference 
50-59 1.26 (0.95-1.67) 1.20 (0.88-1.63) 
60-69 1.56 (1.18-2.05) 1.51 (1.12-2.04) 
70-79 1.63 (1.21-2.21) 1.19 (0.83-1.71) 
80+ 1.72 (1.19-2.47) 1.71 (1.08-2.70) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.44 (1.17-1.77) 1.58 (1.25-2.00) 
2+ 2.30 (1.87-2.81) 1.88 (1.43-2.46) 
Baseline BMIf     
<18 kg/m2 1.91 (0.84-4.34) 1.27 (0.40-4.01) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.30 (1.04-1.62) 1.42 (1.10-1.85) 





 Table 4.6 Continued 
  
 Lower Gastrointestinal Disorders 
  1-5 Years 5-10 Years 
 HR 99% CI HR 99% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.66 (1.38-2.00) 1.35 (1.05-1.74) 
Surgery and chemotherapy 1.71 (1.06-2.76) 2.70 (1.33-5.49) 
Surgery, radiation, and 
chemotherapy 2.38 (1.69-3.35) 1.37 (0.75-2.52) 
Stageb     
Local Reference 
Regional 1.72 (1.41-2.10) 1.13 (0.83-1.55) 
Advanced 1.71 (1.06-2.77) 1.25 (0.46-3.41) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.36 (1.13-1.64) 1.04 (0.82-1.32) 
Grade III (Poorly differentiated) 1.62 (1.28-2.05) 1.22 (0.87-1.70) 
Grade IV (Undifferentiated) 2.48 (1.55-3.97) 0.29 (0.04-2.08) 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 0.97 (0.77-1.24) 1.19 (0.91-1.55) 
2005-2010 0.99 (0.80-1.22) 0.85 (0.64-1.12) 
2011-2012 0.73 (0.53-1.01)  . 
Age at Diagnosisd     
<50 Reference 
50-59 1.86 (1.37-2.53) 1.70 (1.21-2.40) 
60-69 2.22 (1.64-3.00) 1.75 (1.23-2.48) 
70-79 2.29 (1.65-3.19) 1.44 (0.95-2.19) 
80+ 2.18 (1.46-3.26) 1.51 (0.83-2.74) 
Charlson Comorbidity Indexe     
0 Reference 
1 0.92 (0.74-1.15) 1.20 (0.92-1.56) 
2+ 1.05 (0.84-1.32) 1.00 (0.72-1.40) 
Baseline BMIf     
<18 kg/m2 1.38 (0.57-3.38) 2.60 (1.05-6.47) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.21 (0.97-1.52) 1.16 (0.87-1.56) 





Table 4.6 Continued 
  Abdominal Hernia 
  1-5 Years 5-10 Years 
 HR 99% CI HR 99% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.64 (1.29-2.08) 1.63 (1.15-2.30) 
Surgery and chemotherapy 2.45 (1.45-4.14) 3.07 (1.12-8.40) 
Surgery, radiation, and chemotherapy 2.31 (1.51-3.54) 2.33 (1.13-4.81) 
Stageb     
Local Reference 
Regional 1.99 (1.55-2.54) 1.57 (1.05-2.34) 
Advanced 2.47 (1.43-4.28) 2.34 (0.73-7.51) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.35 (1.06-1.72) 1.19 (0.85-1.66) 
Grade III (Poorly differentiated) 2.13 (1.59-2.83) 1.53 (0.98-2.39) 
Grade IV (Undifferentiated) 3.13 (1.74-5.64) 
 
. 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.26 (0.91-1.75) 0.99 (0.68-1.45) 
2005-2010 1.45 (1.08-1.94) 0.86 (0.58-1.26) 
2011-2012 0.97 (0.63-1.48) 
 
. 
Age at Diagnosisd     
<50 Reference 
50-59 1.33 (0.92-1.93) 2.12 (1.21-3.72) 
60-69 1.87 (1.30-2.68) 2.72 (1.56-4.75) 
70-79 1.52 (1.02-2.29) 2.01 (1.06-3.82) 
80+ 1.44 (0.86-2.39) 2.56 (1.14-5.74) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.18 (0.90-1.55) 1.29 (0.88-1.89) 
2+ 1.82 (1.40-2.38) 1.65 (1.09-2.51) 
Baseline BMIf     
<18 kg/m2 0.94 (0.23-3.84) . 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.30 (0.97-1.74) 1.73 (1.13-2.65) 






Table 4.6 Continued 
  Liver Disease 
  1-5 Years 5-10 Years 
 HR 99% CI HR 99% CI 
Treatment Typea     
Surgery only Reference 
Surgery and radiation 1.56 (1.21-2.02) 1.26 (0.87-1.82) 
Surgery and chemotherapy 6.12 (4.19-8.95) 1.96 (0.62-6.21) 
Surgery, radiation, and 
chemotherapy 3.79 (2.65-5.41) 1.65 (0.77-3.56) 
Stageb     
Local Reference 
Regional 1.88 (1.46-2.42) 0.96 (0.60-1.53) 
Advanced 6.18 (4.26-8.96) 1.67 (0.41-6.89) 
Grade b     
Grade I (Well differentiated)  Reference 
Grade II (Moderately differentiated)  1.49 (1.16-1.93) 0.90 (0.64-1.28) 
Grade III (Poorly differentiated) 3.38 (2.58-4.44) 1.05 (0.64-1.73) 
Grade IV (Undifferentiated) 4.61 (2.75-7.74)  . 
Year of Diagnosisc     
1997-2000 Reference 
2001-2004 1.79 (1.26-2.56) 1.10 (0.74-1.65) 
2005-2010 1.83 (1.32-2.53) 1.08 (0.72-1.61) 
2011-2012 1.75 (1.16-2.64)  . 
Age at Diagnosisd     
<50 Reference 
50-59 0.77 (0.56-1.06) 0.76 (0.49-1.18) 
60-69 0.97 (0.71-1.32) 0.73 (0.46-1.15) 
70-79 0.80 (0.55-1.15) 0.88 (0.53-1.49) 
80+ 0.76 (0.47-1.24) 1.14 (0.58-2.26) 
Charlson Comorbidity Indexe     
0 Reference 
1 1.15 (0.87-1.50) 1.17 (0.78-1.74) 
2+ 1.64 (1.25-2.14) 1.94 (1.29-2.92) 
Baseline BMIf     
<18 kg/m2 . . 0.82 (0.11-6.00) 
18-24.9 kg/m2 Reference 
<25-29.9 kg/m2 1.00 (0.75-1.32) 0.94 (0.62-1.44) 
>30 kg/m2 0.94 (0.72-1.23) 0.95 (0.64-1.41) 
Models adjusted for a. Charlson Comorbidity Index, BMI, race, year of diagnosis, and age at 
diagnosis; b. age at diagnosis, diagnosis year, BMI, Charlson Comorbidity Index, Race; c. BMI, 
Charlson Comorbidity Index, race, endometrial cancer type; d. BMI, race, diagnosis year, 
Charlson Comorbidity Index; e.,age at diagnosis, diagnosis year, race; f. Charlson Comorbidity 











Table 4S.1:  Upper gastrointestinal disease risk at 1-5 and >5-10 years after cancer diagnosis among endometrial cancer survivors in 













Models adjusted for baseline BMI, baseline Charlson Comorbidity Index, and race 





  1-5 Years 
  Survivors General Population  
outcome n % n % HR 99% CI 
Upper gastrointestinal disorders 597 22.6 1,997 19.0 1.19 (1.04-1.36) 
Esophageal disorders 247 9.3 848 8.1 1.25 (1.00-1.55) 
Esophagitis 106 4.0 307 2.9 1.43 (1.04-1.96) 
Other esophageal disorders 222 8.4 819 7.8 1.16 (0.93-1.45) 
     Gastroduodenal ulcer (except hemorrhage) 53 2.0 209 2.0 1.07 (0.70-1.64) 
Gastric ulcer 27 1.0 101 1.0 1.14 (0.64-2.04) 
Duodenal ulcer 16 0.6 31 0.3 2.36 (1.00-5.57) 
Peptic ulcer; site unspecified 30 1.1 129 1.2 0.86 (0.47-1.54) 
Gastritis and duodenitis 128 4.8 382 3.6 1.29 (0.96-1.72) 
Acute gastritis 18 0.7 42 0.4 1.71 (0.78-3.79) 
Other specified gastritis 76 2.9 234 2.2 1.37 (0.95-1.97) 
Unspecified gastritis and gastroduodenitis 73 2.8 201 1.9 1.48* (1.03-2.14) 
Duodenitis 18 0.7 50 0.5 1.36 (0.64-2.89) 






The three aims of this study were to investigate the risk long-term, adverse 
cardiovascular, genitourinary, and gastrointestinal outcomes among endometrial cancer 
survivors 1-5 and >5-10 years after diagnosis compared to the general population. Treatment 
type, stage, grade, and age at diagnosis, baseline body mass index (BMI), and baseline Charlson 
Comorbidity Index were also examined as risk factors for several cardiovascular, genitourinary, 
and gastrointestinal outcomes among endometrial cancer survivors. 
This study is the first to examine risk for all available cardiovascular, genitourinary, and 
gastrointestinal outcomes in the electronic medical records of several thousand endometrial 
cancer survivors and matched controls from the general population in a large cohort study. 
 
5.1 Key Findings 
5.1.1 Cardiovascular Outcomes 
While endometrial cancer survivors have been observed to be at higher risk for 
hypertension, this study contributes evidence that endometrial cancer survivors are more likely 
to develop secondary hypertension and hypertensive heart and/or renal disease years after 
diagnosis. Those treated with surgery and radiation were only marginally more likely to be 




treated with surgery alone. Risk for hypertension among endometrial cancer survivors increased 
with each 10 year interval of age at diagnosis compared to those diagnosed before age 50. 
Similar proportions of endometrial cancer survivors who have received a diagnosis of 
hypertension (43-47%) have been previously observed,1,2 but this study is the first to quantify 
risk for hypertension among endometrial cancer survivors compared to the general population. 
Endometrial cancer survivors were at especially high risk of developing circulatory 
system disorders between 1-5 and >5-10 years after diagnosis. Survivors were 2-3 times more 
likely to be diagnosed with phlebitis, thrombophlebitis, or thromboembolism between 1-5 years 
after diagnosis. It is possible that radiation therapy damage to the endothelial cells of the 
vascular system could be implicated.3 The increased risk for circulatory system disorders among 
survivors treated with radiation therapy and/or chemotherapy support previous findings that 
risk for these conditions is elevated among survivors of lymphoma, breast cancer, and head and 
neck cancer who were treated with RT4 and among individuals treated with chemotherapy for a 
variety of cancers.5 Survivors in our study who received radiation therapy and/or chemotherapy 
in addition to surgery were at higher risk for both venous and arterial disease compared to 
those treated with surgery alone.  
 Survivors were at elevated risk for heart disease over all during both time periods and a 
number of additional heart conditions. They were 43% more likely to be diagnosed with 
congestive heart failure 1-5 years and 58% more likely between >5-10 years after diagnosis. The 
70% elevated risk for pulmonary heart disease was confined to the 1-5 year range and no 
increased risk was observed >5-10 years after diagnosis. Chemotherapy is often associated with 
increased risk for heart disease,6,7 and our findings that endometrial cancer survivors treated 
with chemotherapy with or without radiation therapy were at elevated risk between 1-5 years 




disease and is likely related to the treatments indicated for higher grade tumors. 
 
5.1.2 Genitourinary Outcomes 
Those that have examined long-term urinary system disorders among endometrial 
cancer survivors have had mixed results8-10 and have largely focused on conditions such as 
urinary incontinence that may be secondary to many of the outcomes that were measured in 
the study. In this study, endometrial cancer survivors were at elevated risk for nearly all of the 
urinary system disorders that were examined at 1-5 years, with risk persisting at >5-10 years for 
many that have not been previously investigated on this scale. Using data from electronic 
medical records provides a more objective measure of these conditions which may not have 
been captured by patient self-report or were not previously measured. Treatment-related risk 
for urinary system disorders was confined to 1-5 years after diagnosis, but large effect sizes 
were observed over this time period. Survivors treated with chemotherapy were 3 times more 
likely to be diagnosed with a urinary system disorder than those treated with surgery alone. 
Elevated risk was also observed among those treated with radiation therapy and among those 
diagnosed with higher stage and higher grade tumors.  
Survivors were at elevated risk for genital organ disorders between 1-5 and >5-10 years 
after diagnosis. Between 1-5 years after diagnosis, endometrial cancer survivors were 88% more 
likely to be diagnosed with an inflammatory disease of the pelvic organs, but no elevated risk 
was observed after >5-10 years. Unlike urinary system disorders, the number of outcomes 
available for analysis suffered from a lack of granularity in our outcome classification strategy. 
Further, there were a number of outcomes that would not have the potential to be diagnosed in 
endometrial cancer survivors who have undergone total abdominal hysterectomy and bilateral 




genital organ outcomes for analysis. Despite this, elevated risk for genital organ disorders was 
observed among survivors treated with radiation therapy and/or chemotherapy compared to 
those treated with surgery alone. 
  
5.1.3 Gastrointestinal Outcomes 
 This is the first study to observe elevated risk for a new diagnosis of gallstones and 
gallbladder inflammation among endometrial cancer survivors years after diagnosis. Pancreatic 
disorders are also related to BMI, and elevated risk among endometrial cancer survivors 
compared to general population controls was observed. Our results suggest that risk for both 
pancreatic conditions overall and for acute pancreatitis is higher after 5 years than between 1-5 
years. Pancreatitis due to chemotherapy is rare (1.4-2%).11-13 Similarly, evidence for RT-induced 
pancreatitis is scarce and comes primarily from case reports.14-16  
 The largest effect size in this study was observed for liver disease among endometrial 
cancer survivors treated with surgery and chemotherapy compared to those treated with 
surgery alone. These individuals were more than 6 times more likely to be diagnosed with liver 
disease. Chemotoxicity in the liver has been observed in those treated for other cancers, but 
these results are far in excess of what has previously been reported.17-19 This was also the first 
study to observe that risk for liver disease overall was elevated among endometrial cancer 
survivors compared to the general population years after diagnosis. 
 It was suggested that as many as 90% of those treated with radiation therapy 
experience permanent bowel damage.20 The availability of a large amount of GI outcomes in our 
data allowed us to observe whether or not many of these previously observed conditions are 
more common in endometrial cancer survivors >5 years after diagnosis. The effect sizes were 




abscess between 1-5 and >5-10 years after diagnosis, while conditions such as paralytic ileus, 
anal and rectal conditions, and diverticulosis were much more likely among endometrial cancer 
survivors between 1-5 years but not >5-10 years after diagnosis. However, individuals treated 
with surgery in conjunction with radiation therapy and/or chemotherapy were at significantly 
elevated risk of lower gastrointestinal conditions between 1-5 and >5-10 years after diagnosis, 
suggesting long term damage from these treatments is possible. 
 Abdominal hernias have been previously associated with surgical treatment and are 
often diagnosed postoperatively, but our results suggest that newly diagnosed ventral and 
incisional hernias are 3 to 4 times more likely to occur in endometrial cancer survivors even >5 
years since diagnosis. Further, we observed that survivors treated with chemotherapy with or 
without radiation therapy were 2 to 3 times more likely to be diagnosed with an abdominal 
hernia compared to those treated with surgery alone between 1-5 and >5-10 years after 
diagnosis. It is possible that this could be related to more aggressive surgeries being performed 
for higher-risk tumors which might result in more frequent complications or because of the use 
of chemotherapeutic agents that compromise wound healing.21 
These results present a number of important additions to the body of literature 
concerning long-term, adverse cardiovascular, genitourinary, and gastrointestinal outcomes 
among endometrial cancer survivors. Many of the investigations into genitourinary and 
gastrointestinal associations have focused on symptoms that affect health-related quality of life 
among survivors that were measured using self-report from patients on subjects that are 
personal and may be less likely to be reported or lack validated measures (such as diagnosis 
from a clinician) to record outcomes. These results utilize clinician-diagnosed outcomes from 
electronic medical records and contribute to a further understanding of some of the conditions 




5.1.4. Public Health and Clinical Impact 
Over the last several decades, there has been a focus towards measuring not only the 
clinical outcomes of cancer treatment but long-term health effects and quality of life.22 One of 
the primary risk factors related to both endometrial cancer and long-term adverse health 
outcomes is obesity. Obese individuals diagnosed with endometrial cancer have poorer overall 
health outcomes. Interventions intended to reduce the burden of obesity could have a 
significant effect on the constellation of obesity-related illnesses experienced by survivors of 
endometrial cancer. These could take the form of dietary and exercise interventions, and many 
such interventions have been shown to be effective.23-28 
Ultimately, these results may provide clinicians with information necessary to 
understand more about many conditions that adversely affect quality of life among survivors 
and may provide justification for more careful observation and screening for potentially life-
threatening conditions that may be related to treatment for endometrial cancer later in life. 
Results from this study could provide guidance for incorporating information about risk for 
specific disorders into survivorship care plans by clinicians and others working in cancer 
survivorship.  Care for endometrial cancer patients in the years following diagnosis should be 
expanded beyond routine surveillance for disease recurrence to include adverse cardiovascular, 
genitourinary, and gastrointestinal outcomes towards the goal of achieving better quality of life 
for long-term endometrial cancer survivors. 
Future research into long-term, adverse health effects among endometrial cancer 
survivors should include examining the role of genetic susceptibility in risk for multiple 
comorbidities. These results could inform future studies by presenting information that may be 
useful for risk prediction models. In addition, these results could be combined with research into 




comorbidity trajectory of cancer survivors.   
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